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SecA2 is part of a specialized protein export pathway of Mycobacterium 
tuberculosis that is important to virulence.  We present evidence that a ∆secA2 mutant of 
M. tuberculosis is defective for replication in macrophages.  In addition, macrophages 
infected with the ∆secA2 mutant produce more proinflammatory TNF-α, IL-6, and RNI 
than those infected with wild type M. tuberculosis.  These host factors are induced by M. 
tuberculosis through TLR/MyD88 signaling pathways.  The attenuated phenotype of the 
∆secA2 mutant in macrophages was dependent on the signaling adaptor MyD88 and 
TNF-α.  Our data suggests that the role of SecA2 in virulence is to export factors which 
limit the host immune response, and thereby protects the bacillus against MyD88/TNF-α 
dependent defenses.  Finally, we reveal a role for SecA2 in assembling the cell surface 
structure of M. tuberculosis, a finding that may have implications on the biology of the 
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 Mycobacterium tuberculosis and the disease it causes has plagued mankind for 
centuries, and it still remains as much of a global health threat today as ever before.  
Signs of tuberculosis and its symptoms have been described in skeletons from several 
archeological sites dating back to the Bronze Age and Iron Age more than 4000 years ago 
(79, 119).  Greek historians from 500-700 B.C. write of a wasting disease called phthisis, 
marked by chest pain, coughing, and blood in the sputum.  Epidemics of tuberculosis 
(TB) have arisen throughout the course of time.  In the first half of the 19th century, it is 
estimated that up to 25% of Europeans died from tuberculosis (108).  Yet it was not until 
the later part of the 19th century that Robert Koch was able to identify M. tuberculosis as 
the causative agent of tuberculosis, a discovery announced on March 24, 1882 (59).  The 
anniversary of this report each year is marked as World TB Day (115).  Since that initial 
discovery, scientists have learned much about the disease itself, as well as about the 
organism, and yet today we are still faced with the highest global burden of tuberculosis 
ever.  The theme of World TB Day 2007, “TB anywhere, is TB everywhere”, gives us 
 2
perspective on the pandemic, that unless the disease is eradicated in all countries, it will 
continue to be a global health burden. 
 
Disease Process and Epidemiology 
 
Mycobacterium tuberculosis is a rod shaped acid-fast bacillus.  The primary route 
of transmission of M. tuberculosis is via aerosols person to person.  When an individual 
comes into contact with the aerosols, the aerosol droplets containing bacilli are taken up 
into the lungs.  The bacilli are phagocytosed in the lungs by alveolar macrophages, or to a 
lesser extent are ingested by alveolar type II pneumocytes (10, 69).  If the macrophage 
has been preactivated, it will be contain the bacilli and the patient will not develop 
disease.  However, the majority of macrophages are non-activated and are permissive for 
bacterial replication.  When the bacilli enter these resting macrophages they are able to 
combat the defense mechanisms of the macrophage, enabling them to survive and 
replicate.  Once infected, these macrophages secrete chemoattractants, recruiting 
lymphocytes, neutrophils and monocytes to the site of infection (123)(Fig. 1.1).  These 
cells will begin to form a barrier around the infected monocytes, producing a 
granulomatous lesion, and large macrophage derived foamy cells will form at the center 
of the granuloma.  As macrophages and dendritic cells present M. tuberculosis antigens 
to CD4+ and CD8+ T cells, a Th1 cell mediated immune response is mounted (39).  This 
results in amplification of antigen specific T cells, which play a crucial role in inhibiting 
the infection by secreting IFN-γ, which then in turn activates macrophages to control the 
growth of the bacteria.  CD8+ T cells can also inhibit mycobacterial growth 
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 by lysing infected host cells (22, 113). Often the bacteria are held in check at this stage, 
and the infection is considered “latent”. Individuals with a healthy immune system can 
remain latently infected for years, showing no signs of disease.  Individuals who are 
latently infected have a 10% chance in their lifetimes of having the bacilli reactivating to 
cause active disease, while some will resolve the infection entirely.  A decrease in 
immune system function from several factors contributes to disease reactivation, and 
these factors include age, immunosuppressive drugs, malnutrition, and HIV (70). The 
global pandemics of HIV and tuberculosis are having a deadly interplay.  Someone 
infected with HIV, who also has a latent tuberculosis infection, has a 10% per year 
chance of developing an active case of tuberculosis (124).  Tuberculosis kills 1.6 million 
people each year, an average of 4400 per day.  Of these, approximately 200,000 are those 
with HIV/AIDS, making tuberculosis the leading killer of people with HIV/AIDS (124).  
When tuberculosis becomes reactivated, or when the initial infection is not controlled, the 
individual has active disease and is infectious.  
One of the biggest challenges in the fight against tuberculosis is the rise of drug 
resistant forms of the bacterium.  Drug resistance arises when chemotherapeutics are used 
improperly, either due to misprescribed treatments by healthcare workers, patient non-
compliance for completing a drug regimen, poor accessibility to treatment medications, 
or receiving a poor quality treatment (70).  The history of tuberculosis and chemotherapy 
dates back to the very first therapeutics used.  Streptomycin was the first antibiotic 
discovered for human use in 1943, and was used to treat tuberculosis by 1944 (24).  
Within months of use, the first strains of M. tuberculosis resistant to streptomycin began 
to appear (24).  Isoniazid (1952) and rifampin (1963) joined streptomycin as the standard 
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of treatment for tuberculosis, and are still used as frontline treatments today.  However, 
resistant strains of M. tuberculosis exist for each of these drugs.  The concerns about 
mono-resistant strains have now given way to even greater concerns with the emergence 
of multi-drug resistant (MDR), and the newest extensively drug resistant (XDR).  MDR-
TB strains are resistant to at least the two front line drugs isoniazid and rifampin, and 
represent 20% of isolates tested from 2000-2004 (125).  The newly described XDR-TB 
strain is an MDR-TB strain that is also resistant to any fluoroquinolone and is resistant to 
at least one of the second line injectable drugs (capreomycin, kanamycin, amikacin).  
XDR-TB represents 2% of all isolates tested, and 4% of the MDR-TB isolates tested in 
the United States (125). 
 
Vaccine Development 
Robert Koch initiated the first studies to find a vaccine against tuberculosis.  His 
initial attempts to use purified protein and cell wall components from M. tuberculosis to 
vaccinate against infection was unsuccessful in terms of protection against disease, but 
yielded a diagnostic tool for the detection of tuberculosis that is still in practice today 
(100).  M. bovis, a close relative of M. tuberculosis, was passaged by Calmette and 
Guerin to create the attenuated strain BCG (100).  Since the 1920s, BCG has been used as 
a live, attenuated vaccine to prevent M. tuberculosis, with more than four billion doses 
being administered world wide (70).  However, this vaccine has demonstrated varying 
degrees of efficacy in different clinical trials.  BCG immunization has a proven efficacy 
in preventing extrapulmonary tuberculosis in children (122). However, in adults clinical 
trials demonstrate anywhere from 70% effectiveness to no protection, as seen in the 
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largest scale retrospective analysis done in India (70).  Why this vaccine shows such 
varied protection is unclear.  One hypothesis is in certain endemic areas, individuals may 
be more readily exposed to environmental mycobacteria prior to vaccination (27, 83).  
The prior exposure may lead to a greater recognition of BCG by the immune system, and 
clearance of the vaccine before it can confer protection.  Given the variable protection of 
BCG and continued world wide presence of tuberculosis, a better vaccine must be found.  
Many different approaches toward this end are being taken, and include the development 
of subunit vaccines, DNA vaccines, manipulation of BCG to increased efficacy, and use 
of other recombinant mycobacteria to express M. tuberculosis antigens (70).  A better 
understanding of the biology of the organism itself and its relationship with the host 
immune response will help these efforts. 
 
Effectors of the Host Response Against  M. tuberculosis: Cytokines 
To understand how M. tuberculosis evades the immune system, we must first 
understand the host immune effectors capable of controlling mycobacterial infection.  
IFN-γ is an essential cytokine in the defense against M. tuberculosis.  As described, IFN-
γ secretion by T cells is important for mediating granuloma formation.  But perhaps more 
important, is the role that IFN-γ plays in limiting mycobacterial growth through the 
activation of macrophage antimicrobial responses (38, 97).  IFN-γ, in concert with TNF-
α, activates macrophages to inhibit the intracellular growth of mycobacteria, primarily 
through the action of inducible nitric oxide synthase (iNOS) (30, 38).  Mice that are 
deficient in the production of IFN-γ are highly susceptible to an M. tuberculosis infection, 
and the bacteria replicate uncontrollably until the mice succumb to disease (40).  In the 
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murine system, iNOS and the nitrosative burst are one of the most potent host defense 
mechanisms against M. tuberculosis (65).  
However, there are other IFN-γ related loci in the mouse that are key to the 
defense program against mycobacterium.  MacMicking etal first reported a novel IFN-γ 
induced host mechanism for controlling M. tuberculosis, the IFN-γ inducible guanosine 
triphosphatase family LRG-47  (36, 66).  Mice lacking LRG-47 are highly susceptible to 
M. tuberculosis and succumb rapidly to disease.  The action of LRG-47 is independent of 
iNOS, and seems to be directed toward promoting proper phagosome maturation and 
phagosome/lysosome fusion.  Together, iNOS and LRG-47 combine to form the majority 
of the host IFN-γ induced antimycobacterial activity (66).   
The importance of IFN-γ in host protection against tuberculosis has also been 
seen in the clinical setting of human disease.  Patients with mutations in the IL-12/IL-
23/IFN-γ pathways of Type I cytokines or in IFN-γ receptors show an increased 
susceptibility to infection by M. tuberculosis and non-tuberculosis mycobacterium 
(NTM), and an increased severity of disease symptoms (70, 80).  Given its potent role in 
protection against intracellular pathogens, IFN-γ is being investigated as a clinical 
treatment of infections, including M. tuberculosis (95). 
The proinflammatory cytokine TNF-α is also essential for productive immune 
response against TB.  Early studies demonstrated this importance using TNF-α knockout 
mice.  These mice are unable to control the replication of the bacteria, which grow 
uncontrollably, resulting in a rapid mortality in the mice (5, 12, 41). TNF-α is critical for 
granuloma formation and maintenance, and inhibition of TNF-α results in reactivation of 
latent infection in a murine model (72).  There is now data from human subjects and the 
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importance of TNF-α.  A new class of drugs developed to treat chronic inflammation 
from arthritis is specifically targeted to neutralize TNF-α.  Patients treated with these 
drugs are at greater risk for reactivation of latent tuberculosis (70, 101, 112).   
As described, TNF-α works in concert with IFN-γ to activate the macrophage 
antimicrobial effector iNOS (19, 30, 38).  However, if and how TNF-α in the absence of 
IFN-γ inhibits growth of mycobacteria at the cellular level is unclear.  Some studies 
suggest that there are TNF-α dependent mechanisms independent of IFN-γ that either 
inhibit the growth or kill mycobacteria (6, 21, 34, 58, 103).  TNF-α alone can trigger 
iNOS induction and mycobacterial growth inhibition through the production of RNI.  
However, there may also be TNF-α dependent, but iNOS independent, mechanisms of 
growth inhibition (6).  In contrast, there are opposing studies that would suggest that 
TNF-α may even enhance the growth of virulent mycobacteria (17, 34, 92).  The 
discrepancies in these results remain to be resolved and may come from differences in 
cell types and protocols used amongst the labs.    
TNF-α may also exert antimicrobial effects against M. tuberculosis via the 
induction of apoptosis, an effector mechanism that is independent of iNOS and IFN-γ.  
Several reports have shown an apoptosis induced killing or growth inhibition of M. 
tuberculosis (29, 56, 78).  Consistent with this, some avirulent strains of mycobacteria 
induce apoptosis or are incapable of blocking the apoptotic pathway, as shown by several 
of the apoptotic pathway signaling intermediates such as caspases 3, 8, 9, and 10 being 
upregulated during infection.  The levels of apoptosis are related to the levels of bioactive 
TNF-α, and strains inducing higher levels of TNF-α or TNF- α bioactivity induce more 
apoptosis (4, 55, 56, 61, 96, 112).  Data in the literature demonstrates that virulent M. 
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tuberculosis evades apoptosis (4, 55, 110).  Taken together, this data suggests that TNF-α 
may exert antimicrobial effects on M. tuberculosis by the induction of host cell death, a 
mechanism that is independent of iNOS and IFN-γ. 
 
Effectors of the Host Response Against M. tuberculosis: Innate Immunity 
Cytokine production by host cells is triggered as part of an innate host response.   
Key components of innate immunity defense mechanism against M. tuberculosis are the 
mammalian pattern recognition receptors, such as Toll-like receptors (TLR), which 
specifically recognize microbial ligands.  TLR are a family of transmembrane receptors 
that contain an extracellular leucine-rich repeat (LRR) domain and an intracellular 
Toll/IL-1 receptor (TIR) domain (68).  Upon ligand binding, TLR recruit TIR-domain 
containing adaptor protein MyD88, and the accessory adaptor MyD88/TIR domain-
containing adaptor protein (TIRAP) to the receptor (Fig 1.2).  MyD88 is an essential 
signaling component of signaling for all TLR receptors, except TLR3 (91).  A MyD88 
independent signaling pathway using TIR domain-containing adaptor-inducing 
interferon-β (TRIF) is engaged by TLR3, and is important for interferon regulatory 
factors-3 (IRF-3) mediated activity (91).  TLR4 can also utilize this TRIF dependent, 
MyD88 independent pathway, in addition to its signaling through MyD88 (91).   
Activation of MyD88 leads to the formation of the IL-1 receptor associated kinase 
(IRAK) and TNF receptor-associated factor 6 (TRAF6) complexes, which activate NF-
κB, leading to expression of proinflammatory cytokines and regulatory molecules, such 
as TNF-α and IL-12.  TLR activation also activates macrophage antimicrobial effector 
mechanisms, such as inducible nitric oxide synthase (iNOS), and modulate the  
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developing adaptive immune response by influencing dendritic cell (DC) maturation and 
T-cell activation (31).  Furthermore, TLR signaling may play a role in the regulation of 
phagosome maturation and subsequent antigen presentation, although there is some 
controversy surrounding this model (11).   
M. tuberculosis is able to activate cells through interactions with TLR2, TLR4, 
and TLR9 to produce host effectors such as TNF-α, IL-6 and RNI via the adaptor protein 
MyD88, and progress has been made in identifying M. tuberculosis surface molecules 
that are TLR ligands [Reviewed in (50, 52, 91, 114)].  These TLR agonists include lipids, 
such as lipomannan (LM) and lipoarabinomannan (LAM), lipoproteins, and protein 
molecules.  The TLR agonists of M. tuberculosis are found both associated with the 
surface of the bacterium, as well as exported into the extracellular space.  The M. 
tuberculosis agonists signal primarily via TLR2, but TLR4 also plays a role.  In addition, 
M. tuberculosis DNA is recognized by TLR9.  TLR pathways play an important role in 
the host response to several pathogens, and studies of the specific role(s) of this system in 
host protection against M. tuberculosis are underway.  Studies using mice deficient in 
either TLR2, TLR4, TLR9 or MyD88, or having multiple deficiencies, have been tested 
for their susceptibility to M. tuberculosis infection.  While the roles of TLR2 and TLR4 
are unclear, mice missing MyD88 or TLR9/TLR2 have a drastically increased 
susceptibility to M. tuberculosis, supporting a role for these TLR pathways in host 
protection (1, 3, 13, 31, 37, 44, 51, 54, 75, 94, 99, 104, 106, 116, 121).  This also suggests 
that there is redundancy in the function of the TLR, in that the TLR9/TLR2 double 
knockout has a more dramatic phenotype than either of the individual mutants.  The data 
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using the MyD88 knockout mice shows that TLR signaling through this adaptor is 
important for host defense against M. tuberculosis. 
 
Effectors of the Host Response Against M. tuberculosis: Adaptive Immunity 
In addition to an innate immune response against mycobacteria, an infected host 
must also mount an adaptive immune response to control infection.  The protective 
immune response to M. tuberculosis is a cell-mediated Th1 response involving both 
CD4+ and CD8+ T cells (18, 42, 71, 109, 118).  As described, CD4+ cells are recruited to 
the site of a nascent granuloma and represent an important source of IFN-γ, essential for 
the control of M. tuberculosis.  CD8+ T cells can also inhibit mycobacterial growth by 
lysing infected host cells (22, 113).  Depletion of CD4+ T cells results in the reactivation 
of tuberculosis in both humans and mice, showing the importance of these immune 
effector cells in controlling M. tuberculosis (105). 
In addition to a T cell response, M. tuberculosis infection elicits a humoral 
response.  Although the antibody response to M. tuberculosis is not likely to contribute to 
the control of infection, antigens recognized by host antibodies could be the basis of 
serodiagnostic techniques for tuberculosis (46, 48, 53).   
 
Intracellular Survival Mechanisms of Mycobacteria 
In prior sections, we described the host immune responses involved in controlling 
a mycobacterial infection.  However, M. tuberculosis is a successful pathogen, which has 
evolved mechanisms to thwart many of the antimicrobial host responses.  When it first 
enters the lungs of a nascent host, the bacterium must invade and replicate within host 
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cells.  Here we will discuss four mechanisms by which M. tuberculosis survives in the 
non-activated host cell.  This first step in the infection process is important, as without 
intracellular growth the infection cannot continue and there will be no disease.  M. 
tuberculosis is phagocytosed by monocytes a process triggered via several host receptors, 
including the complement receptors, scavenger receptor and mannose receptor (35).  
During the normal process of phagocytosis, a particle or organism is taken up into a 
phagosome.  As the phagosome matures it acquires markers such as Rab5 and EEA1, and 
these markers direct fusion of the phagosome with endosomal vesicles.  Aqcuisition of 
the late markers Rab7 and LAMP1 promote subsequent fusion with lysosomal vesicles 
(60).  Fusion with the lysosome delivers hydrolytic enzymes, such as cathepsin D, which 
digest the bacteria.  During maturation the phagosome also acidifies as the vacuolar H+-
ATPase is recruited.  The resultant low pH is harmful to the bacteria contained within the 
cell, and also activates antimicrobial protease activity (60, 98).  Mycobacteria alter the 
normal phagosome maturation pathway, and this is proposed to be an important 
mechanism for survival.  Once in the phagosome, M. tuberculosis is able to block 
acquisition of the vacuolar H+- ATPase, thus preventing acidification of the phagosome 
(Reviewed in (28).  The phagosome is also blocked at other stages of maturation, and 
does not acquire late endosomal markers Rab 7 and LAMP1, and does not fuse with 
lysosomes (60).  This prevents the delivery of lysosomal hydrolytic enzymes to the M. 
tuberculosis phagosome.  Several recent reports have suggested the importance of the 
inhibition of phagolysosome fusion to the pathogenesis of M. tuberculosis.  Studies have 
uncovered mutants of M. tuberculosis that are defective for this process, and are 
attenuated for growth in macrophages (63, 87).  However, there was also a subset of 
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mutants in this screen that did not inhibit phagolysosome fusion and ended up in mature 
phagolysosomes, and yet grew to wild type levels.  Clearly there is complexity to the 
survival of M. tuberculosis in the context of the phagosome, but this remains one possible 
mechanism of intracellular survival for M. tuberculosis. 
The second survival mechanism is the ability of M. tuberculosis to combat the 
toxic effects mediated by reactive nitrogen and reactive oxygen intermediates produced 
by the host cells.  Enzymes that can detoxify these radicals are an important defense 
mechanism.  In M. tuberculosis, there is a precedent for the importance of such enzymes, 
including the superoxide dismutases SodA (secreted) and SodC (surface localized), and 
the catalase-peroxidase KatG (secreted), in pathogenesis and protection against the 
oxidative burst of macrophages (32, 33, 67, 74, 88).  Reactive nitrogen intermediates are 
a potent antimycobacterial effector in the murine host, and mice defective for iNOS have 
a dramatically increased susceptibility to mycobacterial infection (65).  M. tuberculosis 
can limit its sensitivity to RNI.  One such protective mechanism is via the production of a 
proteosome (25).  The proteosome and proteosome associated proteins Mpa and PafA 
function to maintain the levels of enzymes required for fatty acid and polyketide 
synthesis, and these enzymes are important for pathogenesis and mycobacterial 
metabolism (85).  The role of the proteosome in protecting against RNI is likely the 
degradation of proteins damaged by the nitrosative burst. 
A third survival mechanism of M. tuberculosis is the acquisition of nutrients 
inside host cells.  Inside macrophages nutrients are sequestered away from the invading 
organism, so nutrient acquisition and alternative metabolic pathways are important 
mechanisms to promote intracellular.  Metals such as iron and magnesium are essential to 
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life, and intracellular pathogens must produce molecules to scavenge these away from the 
host.  M. tuberculosis produces MgtC, a magnesium transporter, and Mbt, an iron 
scavenging siderophore operon, which are both essential for the full virulence of the 
organism (16, 26, 90).  When growing inside a host, M. tuberculosis preferentially shifts 
its metabolism to pathways that use fatty acids versus carbohydrates.  Thus, enzymes 
involved in the fatty acid metabolism pathways of M. tuberculosis are important for 
virulence, such as the isocitrate lyase enzymes (Icl1/Icl2).  M. tuberculosis strains with 
mutations these enzymes are attenuated for growth in macrophages, supporting the idea 
that M. tuberculosis must alter its metabolic pathways inside the host cells in order to 
survive Munoz-Elias, 2005 #1309}. 
The fourth mechanism employed by M. tuberculosis is its ability to inhibit 
macrophage activation.  As has been discussed, IFN-γ mediated host responses are 
critical to controlling M. tuberculosis.  M. tuberculosis has evolved mechanisms to inhibit 
a subset of IFN-γ induced pathways (60).  M. tuberculosis interferes with the signaling 
pathway downstream of the IFN-γ receptor, preventing the activation of transcription 
factors, and subsequently inhibiting the production of a subset of host responses, 
including cytokines, chemokines, and components of the MHC class II antigen 
presentation pathway (43, 57, 81, 82, 120).  M. tuberculosis inhibits IFN-γ stimulation of 
MHC class II molecules, which are an integral component of the antigen presentation 
pathway to MHC class II restricted CD+4 T cells (43, 57, 81, 82, 120).  Lipoproteins of 
M. tuberculosis, such as the well characterized 19kDa lipoprotein, are important for 
inhibition of IFN-γ pathways via prolonged signaling through TLR2 (43, 45, 47, 57, 76, 
77, 81, 82, 86, 120).  However, it is still unclear if M. tuberculosis inhibition of MHC 
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class II antigen presentation results in a diminished T cell response in a whole animal 
model.  
 In addition to inhibiting IFN-γ mediated signaling pathways, M. tuberculosis has 
also been shown to inhibit other cytokine responses of macrophages.  It was previously 
demonstrated that virulent M. tuberculosis could inhibit an IL-12 response elicited by 
Escherichia coli if the bacteria were coinoculated (73). The importance of immune 
modulation has also been demonstrated with several hypervirulent strains of M. 
tuberculosis, which elicit decreased levels of proinflammatory cytokines.  This 
phenomenon has been described for the hypervirulent HN878 strain of M. tuberculosis 
and the hypervirulent mce1 mutant of M. tuberculosis (67, 93, 107).  The hypervirulent 
strain HN878 produces a polyketide-derived phenolic glycolipid (PGL) (93).  The 
production of PGL dampens the host immune response, resulting in hypervirulence.  
Disruption of PGL biosynthesis results in an increase in cytokine induction and in a loss 
of hypervirulence (93).   Mce1 is a surface associated protein of M. tuberculosis (20).  
When mce1 is disrupted, the resultant M. tuberculosis mutant induces less 
proinflammatory cytokines and is hypervirulent in a murine infection (107). 
In addition to surface associated factors of M. tuberculosis that can modulate the 
immune response, there is a recent report that secreted proteins of M. tuberculosis also 
function to dampen the host response.  It was recently shown that ESAT-6, an antigen 
exported by M. tuberculosis by a specialized esx-1 export pathway, is able to bind TLR2.  
Once bound, ESAT-6 can suppress downstream TLR signaling by activating the kinase 
Akt, which in turn inhibits the interaction of MyD88 and its catalytic partner IRAK4, thus 
abrogating the signaling of MyD88 (84).  ESAT-6 was able to block the induction of 
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cytokines such as IL-12 and TNF-α via its interaction with TLR2 (84).  An ESAT-6 
mutant of M. tuberculosis, or mutants in the ESAT-6 export pathway, show increased 
cytokine induction compared to the wild type strain (64, 111), which would result from 
the loss of the TLR inhibitory actions of ESAT-6.  
Taken together, these reports demonstrate that surface and secreted molecules of 
M. tuberculosis can modulate the host immune response, a process that may promote the 
virulence of the organism.  
 
Protein export and the accessory SecA2 export pathway 
The proper localization of proteins is not only essential for the viability of all organisms, 
but contributes to the virulence of many pathogens.  To understand how M. tuberculosis 
is able to survive in the host, we must first have a basic understanding of the biology of 
the bacterium, including protein export pathways.   Proteins are synthesized in the 
cytoplasm.  While some proteins remain in the cytoplasm, other must be transported out 
and localized to other subcellular compartments for proper function.   
The essential process of protein translocation in bacteria is mediated by the Sec 
protein export pathway.  The Sec pathway is ubiquitous in all bacteria and is essential for 
bacterial viability.  The Sec pathway is comprised of several components including SecA, 
an ATPase, and SecYEG, integral membrane proteins which form the protein export 
channel.  SecA functions as a dimer, and interacts with the signal peptide of a nascent 
preprotein and SecYEG to promote protein export across the inner membrane (Fig. 1.1).  
The ATPase function of SecA is essential to this process, and SecA is essential for the 
viability of all bacteria.   
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In Gram-negative organisms, there are alternate export pathways that localize 
proteins across the outer membrane of the bacteria, and often directly translocate 
virulence factors into host cells.   These alternate protein export pathways represent a 
powerful virulence mechanism for Gram-negative pathogens (23, 89, 102).  While the 
specialized secretion systems of Gram-negative bacteria have been well characterized, we 
are now only beginning to uncover the specialized secretion systems for Gram-positive 
organisms and mycobacterium species.   
One of the first such specialized protein export systems to be identified is the 
SecA2 pathway.  Recent genome sequences have uncovered multiple copies of SecA in 
the genomes of several Mycobacterium species, as well as in several Gram positive 
organisms.  Among the Gram-positive species that have multiple SecA loci there are 
several pathogens, including Listeria monocytogenes, Streptococcus gordonii, and 
Streptococcus parasanguis.  In M. tuberculosis and M. smegmatis, there is one additional 
copy of SecA.  As reported by Braunstein etal (14), in M. smegmatis, SecA1 is the 
“housekeeping” SecA that is essential for viability of the bacterium, as it can not be 
deleted from the bacteria without an additional copy being provided.  SecA2 is the 
“accessory” SecA protein, which is non-essential and can be deleted from M. smegmatis 
and M. tuberculosis (15).  SecA1 and SecA2 can not functionally complement each other, 
suggesting that they have independent roles in the bacterium.  The ∆secA2 mutant of M. 
smegmatis has several altered phenotypes when compared to the wild type organisms, 
including hypersensitivity to sodium azide, an inhibitor of ATPase activity, and a growth 
defect in rich growth medium (14).  This demonstrates that SecA2 is functional in M. 
smegmatis.  For the other examples of Gram-positive pathogens with multiple copies of 
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SecA, it has also been shown that one copy represents the essential, “housekeeping” 
SecA, while the other SecA is non-essential.  We hypothesized that the accessory SecA2 
of M. tuberculosis would function in virulence.  The investigations into this hypothesis 
are discussed later. 
 
Substrates of the accessory SecA2 export pathway 
There is evidence that SecA2 promotes the export of a specific subset of 
mycobacterial proteins.  Gibbons etal used a proteomic approach to identify SecA2 
dependent proteins in the cell wall of M. smegmatis (49).  Comparing the protein profiles 
of cell wall and cell membrane preparations from wild type M. smegmatis and a ∆secA2 
mutant using two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), revealed 
two proteins whose export to the cell surface is dependent on SecA2.  Proteomics 
identified these proteins to be two lipoproteins.  Homology predicts that these are sugar-
binding lipoproteins.  These lipoproteins also have traditional Sec signal sequences.  
These proteins have no homologs in M. tuberculosis, yet when they are expressed in M. 
tuberculosis, they are recognized by SecA2 (49).  It is important to note that there are 
many lipoproteins in both M. smegmatis and M. tuberculosis that are exported by SecA2 
independent mechanisms, and only a small subset depend on SecA2 for export, indicating 
specificity in SecA2 dependence.   
A similar proteomics study by Braunstein etal (15), examined the proteins 
released into the culture filtrate in wild type M. tuberculosis and in a ∆secA2 mutant by 
2D-PAGE.  Three proteins show diminished export in a ∆secA2 mutant, including the 
antioxidant enzymes superoxide dismutase (SodA) and catalase-peroxidase (KatG).  
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Antioxidant enzymes function in virulence to prevent bacteria from the harmful effects of 
the oxidative burst.  In contrast to the SecA2 dependent lipoproteins found in M. 
smegmatis, SodA and KatG of M. tuberculosis are secreted via SecA2 but lack any 
recognizable signal peptide (15).   Interestingly, L. monocytogenes also exports a 
superoxide dismutase (MnSod) lacking a signal peptide in a SecA2 dependent manner 
(2).  The MnSod of L. monocytogenes is also an important virulence factor (2).  Given 
that the identified SecA2 substrates of M. tuberculosis have a potential role in 
pathogenesis, we hypothesized that SecA2 of M. tuberculosis would also be important for 
virulence.  We investigate the role of SecA2 in the pathogenesis of M. tuberculosis in 
Chapter 2.     
The SecA2 dependent proteins identified in M. tuberculosis and M. smegmatis 
demonstrate heterogeneity in substrates, some that contain traditional signal peptides and 
some that do not.  While some of the factors that act in concert with SecA2 to promote 
protein export have been described for at least one organism, how SecA2 works in 
mycobacteria and what factors it interacts with remain to be elucidated.  In the Gram-
positive pathogen Streptococcus gordonii, SecA2 works with an accessory copy of SecY, 
SecY2, to promote export (8, 117).  However, in mycobacteria there are no accessory 
copies of SecY, SecE, or SecG.  We propose several potential models for the role of 
SecA2 in protein export, which are depicted in Fig. 1.3.  As mentioned, SecA functions 
as a dimer.  The first model is one in which SecA2 also functions as a homodimer, to 
promote the export of a subset of proteins independently of SecA1.  In a second model, 
SecA2 would interact with SecA1 to form a heterodimer, and this complex would 
recognize a specific subset of proteins.  In the third model, SecA2 combines with a set of 
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 as yet undescribed proteins to promote export.  It is also unknown whether or not SecA2 
and any complexes it forms interact with the SecYEG channel, or with a novel membrane 
complex to facilitate export.   
There may in fact be multiple roles for SecA2 in promoting protein export: one in 
which SecA2 promotes the export of a subset of signal-peptide containing proteins, such 
as those identified in M. smegmatis, and another in which SecA2 promotes the export of 
substrates which lack a conventional signal peptide, such as those identified in M. 
tuberculosis.  SecA2 may work in conjunction with SecA1 or SecYEG to promote a 
subset of proteins that contain traditional signal peptides.  Given that there is only a small 
subset of signal-sequence containing proteins that are SecA2 dependent, proteins may 
span a continuum from being exclusively SecA1 dependent to exclusively SecA2 
dependent.  Those in the middle of the spectrum would be proteins dependent on both 
SecA1 and SecA2 for export.  For the non-signal peptide bearing proteins, SecA2 may 
function to export a signal-peptide containing protein to the cell envelope, which is itself 
a component of a novel secretion system.   There must be an undefined characteristic of 
either the signal peptide, the mature protein domain, or in the combination of the two that 
determines SecA2 dependence.  For the SecA2 substrate GspB of S. gordonii, several of 
these SecA2 targeting determinants have been described, but for the substrates of SecA2 
in mycobacteria they still have yet to be determined (7, 9).  Studies currently underway in 
our laboratory hope to elucidate the mechanism by which SecA2 promotes export and 
interacting proteins.   
The SecA2 export pathways of the Gram-positive pathogens L. monocytogenes, S. 
gordonii, and S.  parasanguis, and of M. tuberculosis and M. smegmatis represent a 
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highly specialized route of protein export.  In each of these organisms there is a very 
small subset of proteins that are exported via SecA2, ranging from 17 known substrates 
in L. monocytogenes to one, GspB, in S. gordonii (8, 62, 117).  These SecA2 dependent 
proteins include examples of those with signal peptides and those without signal peptides, 
as well as include examples localized to the bacterial cell and examples that are secreted. 
   
 
The role of the M. tuberculosis SecA2 pathway in virulence 
 SecA2 plays a distinct role in the virulence of L. monocytogenes (62).  SecA2 
may also contribute to the pathogenesis of S. parasanguinis and S. gordonii, given that 
the identified substrates of the SecA2 export pathway in these organisms are predicted to 
function in virulence (62).  In M. tuberculosis, we are just beginning to understand how 
SecA2 promotes virulence.  Braunstein etal (15) demonstrated that an M. tuberculosis 
∆secA2 mutant is attenuated for virulence in a whole animal model of infection using tail 
vein injection.  
 
Summary of Thesis Findings 
 In this work, we expanded studies on the role of SecA2 in the virulence of M. 
tuberculosis.  In Chapter 2, we will present evidence that the ∆secA2 mutant of M. 
tuberculosis is defective for replication in macrophages.  Compared to macrophages 
infected with wild type M. tuberculosis, cells infected with the ∆secA2 mutant show a 
more robust immune response, as demonstrated by increased production of the 
proinflammatory cytokines TNF-α and IL-6, and RNI.  These host factors are controlled 
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by TLR signaling through MyD88.  Our data suggests that the role of SecA2 in virulence 
is to export factors which modulate the host immune response, therefore promoting 
virulence.  In Chapter 3, we demonstrate that the attenuated phenotype of the ∆secA2 
mutant in macrophages depends on host defense mechanisms controlled by the host 
signaling adaptor MyD88 and by the proinflammatory cytokine TNF-α.  Wild type M. 
tuberculosis is resistant to host effects mediated by MyD88/TNF-α, and the ∆secA2 
mutant is more susceptible to these effects.  This suggests that the role of SecA2 in 
promoting virulence in M. tuberculosis is to protect the bacterium against these 
MyD88/TNF-α dependent host immune effectors.  In Chapter 4, we reveal a role for 
SecA2 in promoting the proper cell surface structure of M. tuberculosis, a finding that 
may have implications on the biology of the organism.  Many cell surface associated 
factors of M. tuberculosis have a role in immune modulation and promoting virulence.  
 Perhaps the altered surface of the ∆secA2 mutant contributes to its attenuation due to 
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The SecA protein is present in all bacteria, and it is a central component of the general Sec-
dependent protein export pathway.  An unusual property of Mycobacterium tuberculosis is the 
presence of two SecA proteins: SecA1, the essential “housekeeping” SecA, and SecA2, the 
accessory secretion factor.  Here we report that a ∆secA2 mutant of M. tuberculosis was defective 
for growth in the early stages of low dose aerosol infection of C57BL/6 mice, a time during which 
the bacillus is primarily replicating in macrophages.  Consistent with this in vivo phenotype, we 
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found that the ∆secA2 mutant was defective for growth in macrophages from C57BL/6 mice.  The 
∆secA2 mutant was also attenuated for growth in macrophages from phox-/- mice and from NOS2-/- 
mice.  These mice are defective in the reactive oxygen intermediate (ROI) generating phagocyte 
oxidase or the reactive nitrogen intermediate (RNI) generating inducible nitric oxide synthase, 
respectively.  This indicated a role for SecA2 in the intracellular growth of M. tuberculosis that is 
independent of protecting against these ROI or RNI.  Macrophages infected with the ∆secA2 
mutant produced higher levels of TNF-α, IL-6, RNI and IFN-γ induced MHC class II.  This 
demonstrated a function for M. tuberculosis SecA2 in suppressing macrophage immune responses, 
which could explain the role of SecA2 in intracellular growth.  Our results provide another 
example of a relationship between M. tuberculosis virulence and inhibition of the host immune 




 Mycobacterium tuberculosis, the causative agent of tuberculosis, is one of the most 
successful bacterial pathogens of all time.  The global burden of tuberculosis is at its highest level 
ever and includes an increasing number of multiple drug resistant M. tuberculosis infections (74).  
Novel anti-tuberculosis prevention and treatment measures are needed to control this health crisis, 
and a complete understanding of M. tuberculosis pathogenesis will help achieve this goal. 
M. tuberculosis is inhaled and taken up by unactivated host macrophages where it is able to 
replicate and survive.  Much remains to be learned about how M. tuberculosis avoids host defenses 
in these macrophages.  The processes involved are likely complex and multifactorial.  Among the 
properties implicated in M. tuberculosis survival in macrophages is the ability of the bacillus to 
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block acidification of the phagocytic vacuole, to block phagosome-lysosome fusion, and to resist 
reactive oxygen and nitrogen intermediates (ROI and RNI) (34, 67).   
The early innate immune response to M. tuberculosis includes Toll-like receptor (TLR) 
stimulation of macrophages (35, 55).  TLR signaling leads to the secretion of RNI and pro-
inflammatory cytokines that include TNF-α and IL-6.   Later in infection, activation of host 
macrophages by an adaptive TH1 immune response occurs leading to the inhibition of intracellular 
growth and control of M. tuberculosis infection.  IFN- γ is an important mediator of this response; 
it upregulates antimycobacterial processes and antigen presentation by macrophages (22).  One of 
the antimycobacterial effectors induced by IFN-γ is RNI, which is produced by the inducible nitric 
oxide synthase (NOS2), although other IFN-γ-dependent effector mechanisms exist (13, 39, 40).  
TNF-α is another cytokine that plays an integral role in host control of M. tuberculosis infection (6, 
8, 23).  Among the many properties reported for TNF-α is that it can synergize with IFN-γ to 
induce potent antimycobacterial activity of macrophages (13, 21, 22) 
It is increasingly apparent that M. tuberculosis can limit the host immune response and 
macrophage activation, and that this inhibition is likely to be important to survival in macrophages 
(34).  Although dependent on experimental conditions, there are several reports of macrophages 
infected with more virulent M. tuberculosis producing lower levels or activities of TNF-α and/or 
RNI in comparison to macrophages infected with less virulent or attenuated mycobacteria (2, 7, 20, 
58, 65).  In a more direct fashion M. tuberculosis has been shown to suppress expression of 
Escherichia coli induced pro-inflammatory IL-12 (45).  M. tuberculosis is also known to inhibit 
IFN-γ upregulation of genes including the major histocompatibility complex (MHC) class II genes 
(25, 43, 50, 53).  Inhibition of MHC class II reduces antigen presentation which has implications 
for development of an effective TH1 response in vivo.  
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A common theme in bacterial pathogenesis is the importance of protein export and 
secretion pathways of the pathogen to virulence.  These pathways export proteins beyond the 
cytoplasm to the cell surface or secrete proteins out of the bacterium.  Both surface and secreted 
proteins are exposed to the external environment.  As a result, these proteins are ideally positioned 
to protect the bacterium from macrophage attack or to modify the host immune response to the 
bacillus (14, 36).  Like all bacteria, M. tuberculosis has the conventional Sec pathway and Sec 
proteins for exporting proteins beyond the cytoplasm (36).  More unusual is the presence of two 
SecA proteins (SecA1 and SecA2) in M. tuberculosis (9).  We have shown that the SecA2 protein 
of M. tuberculosis is an accessory secretion factor that promotes secretion of a subset of proteins 
that include superoxide dismutase (SodA) and catalase-peroxidase (KatG) (10).  Both of these 
enzymes detoxify oxygen radicals: SodA converts superoxide to hydrogen peroxide and oxygen 
and KatG converts hydrogen peroxide to water and oxygen.  KatG is also able to break down 
peroxynitrite which is a dangerous reaction product of superoxide and nitric oxide (72).  SecA2 
contributes to the virulence of M. tuberculosis as shown previously using a ∆secA2 mutant of M. 
tuberculosis in a high-dose murine model of tuberculosis (10).   
Here, we describe our studies of the ∆secA2 mutant of M. tuberculosis in an aerosol model 
of murine infection and in murine bone marrow derived macrophages.  Our results with the two 
models were consistent and revealed a role for SecA2 in promoting M. tuberculosis growth early 
in murine infection and in unactivated macrophages.  Using macrophages from phox-/- and NOS2-/- 
mice we further showed that the role of SecA2 is not simply explained by a failure to resist ROI 
produced by the phagocyte oxidase or RNI produced by the inducible nitric oxide synthase.  In 
comparing macrophage responses to infection with the ∆secA2 mutant or parental H37Rv M. 
tuberculosis, we discovered that macrophages infected with the ∆secA2 mutant were more 
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activated on the basis of several criteria: increased TNF-α, IL-6, RNI, and IFN-γ regulated MHC 
class II.  This indicated a role for SecA2 in M. tuberculosis inhibition of the immune response 
which is likely important to survival in the host and pathogenesis.          
 
Materials and Methods 
 
Bacterial Strains and Growth Conditions 
The Mycobacterium tuberculosis strains used in this study H37Rv, mc23112 (∆secA2 mutant, stock 
derived from a single colony) and mc23116 (∆secA2, attB::secA2) (10) were grown in 
Middlebrook 7H9 broth (Difco) with 0.2% glycerol, 1X ADS (albumin dextrose saline) and 0.05% 




Female C57BL/6 mice were purchased from Charles River Laboratories.  p47phox-/- mice were 
generated and maintained as described previously (4).  gp91phox-/- mice and NOS2-/- mice were 
purchased from Jackson Laboratories.  All mice were housed in sterile microbarrier cages and 
were given autoclaved food and water ad libitum.  Both strains of phox-/- mice were maintained on 
an antibiotic oral suspension of sulfamethoxazole (200mg/5ml) and trimethoprim (40mg/5ml) (Hi-




Female C57BL/6 mice ages 38-45 days were used for the aerosol studies.  The M. tuberculosis 
strains were cultured to mid-log phase (OD600~ 0.5-1.0). The cultures were washed one time and 
resuspended in phosphate buffered saline (PBS) with 0.05% Tween 80 (PBS-Tw) to a 
concentration of 1 x 107 CFU (Colony Forming Units)/ml.  The bacterial suspension was placed 
into the nebulizer jar of a whole body exposure aerosol chamber (Mechanical Engineering 
Workshop, Madison, WI).  Mice were exposed for 15 minutes with a chamber purge time of 20 
minutes.  At specific timepoints, four mice were sacrificed from each group by CO2 asphyxiation 
and the lungs, livers and spleens removed and homogenized in PBS-Tw with 100ng/ml 
cycloheximide and 50µg/ml carbenicillin.  The homogenates were plated onto 7H10 ADS glycerol 
plates with 10mg/ml cycloheximide for CFU enumeration. 
 
Macrophage Infections 
Bone marrow derived macrophages were prepared from C57BL/6, p47phox-/-, gp91phox-/-, and NOS2-
/-  mice as follows.  Mice were sacrificed by CO2 asphyxiation and the femurs were removed.  The 
cells were flushed out of the femurs using supplemented DMEM (Sigma) containing 10% heat-
inactivated fetal bovine serum (HI-FBS), 2mM glutamine and 1X non-essential amino acids 
(NEAA).  Cells were washed twice and cultured in supplemented DMEM for 6 days in the 
presence of 20% L929 conditioned medium (LCM).  After 6 days, the cells were removed using 
5mM EDTA (in PBS), washed twice with supplemented DMEM, and resuspended in 
supplemented DMEM with 10% LCM.  The cells were then seeded into the wells of either an 8-
well chamber slide (2 x 105 macrophages/well), or a 24-well plate (8 x 105 macrophages/well) and 
were allowed to adhere overnight before infection.  In some experiments, the macrophages were 
pretreated for 24 hours with 10ng/ml recombinant murine ΙFN-γ (rmΙFN-γ) (Chemicon) before 
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infection.    M. tuberculosis strains were taken from mid-log growth phase and washed one time in 
PBS-Tw.  Cells were resuspended in PBS-Tw and further diluted to the appropriate CFU/ml in 
supplemented DMEM.   The bacteria were added at the appropriate concentration to the cell 
monolayers to achieve a multiplicity of infection (MOI) of 1 or 10.  Macrophages were infected 
for 4 hours, at which time the monolayers were washed three times with supplemented DMEM to 
remove any non-cell associated bacteria, and then fresh media with 10% LCM was added back.  At 
various timepoints, the media was removed from the wells and the cells were lysed with 0.1% 
Tween 80 and vigorous pipetting.  Lysates were diluted in PBS-Tw and plated onto 7H10 ADS 
glycerol 0.05% Tw plates for enumeration of CFU. 
 
RNI measurements 
To measure RNI we used the Griess Reagent (Molecular Probes) and followed the manufacturer’s 
protocol.  Briefly, supernatants from infected macrophage monolayers were filter- sterilized twice 
using a 0.2µm low-protein binding filter, and mixed 1:1 with Griess reagent.  Samples were 
measured at 548nm, and the values converted to µM nitrite using a standard curve generated with 
sodium nitrite.   
 
In Vitro Sensitivity Assays 
Bacteria were grown to mid-log phase in 7H9 ADS glycerol Tw, washed, and diluted to a density 
of approximately 1 x 106 CFU/ml in PBS-Tw.  Percent killing was determined for each strain by 
comparing the number of CFU from treated samples to untreated samples.  The following 
treatments were employed: heat shock (53oC for 45 minutes) and acid pH (pH4.0 for 24 hours).  In 
vitro ROI killing assays were performed using various compounds.  We tested sensitivity to 
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hypoxanthine/xanthine oxidase (0 and 3 hours):  (250µΜ hypoxanthine) (Sigma)/xanthine oxidase 
(0.1U/ml xanthine oxidase) (Roche) in the presence or absence of catalase (1U/ml) (Sigma), added 
to detoxify hydrogen peroxide generated (16, 54).   Other ROI generating compounds tested 
include hydrogen peroxide (0, 5, 10mM for 4 hours), plumbagin (0.2mM for 3.5, 7.5, 10.5 hours), 
pyrogallol (2mM for 0, 1, and 4 hours), and cumene hydroperoxide (0.5mM for 0, 1 and 4 hours) 
(Sigma).  In vitro sensitivity to RNI was tested using spermidine nonoate (SPER/NO) (200µM for 
0 and 4 hours)(Alexis Biochemicals).  All in vitro ROI and RNI assays were performed at 37oC.   
 
Cytometric Bead Array (CBA) 
Infection of bone marrow derived macrophages was performed as described above, infecting cells 
at MOI of 1.  Supernatants were collected from the infected macrophages at 24 hours post 
infection and filtered twice through a 0.22µm low-protein binding filter and supernatants were 
stored at -80oC.  CBA was performed using the Mouse Inflammation CBA Kit (BD Biosciences) 
according to the manufacturer’s protocol.  Samples were analyzed on a BD Biosciences 
FACSCalibur flow cytometer.  The triplicate samples for each strain were averaged and the data is 
shown as the mean ± standard deviation. 
 
Quantitative Real Time-PCR (qRT-PCR) to measure IFN-γ responses of infected 
macrophages 
Murine bone marrow derived macrophages were prepared and infected as described above at an 
MOI of 10 for 3 hours, at which time unincorporated bacteria were washed off and fresh media 
added back to the monolayers.  After 21 hours post-infection, the media was removed from the 
monolayers and replaced with fresh medium containing 2ng/ml rmIFN-γ.  After 15 hours of 
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rmIFN-γ treatment, the supernatants were removed, and the monolayers lysed with TRIzol reagent 
(Invitrogen). The human monocytic cell line THP-1 (ATCC TIB-202) was maintained in 
supplemented RPMI with 10% HI-FBS.  To prepare the THP-1 cells for infection, they were 
washed twice in fresh RPMI with FBS, resuspended in RPMI with FBS containing 50ng/ml 
phorbol myristate acetate (PMA) (Sigma), and seeded into 6-well tissue culture plates at 2 x 106 
cells/well.  After 24 hours PMA treatment, the cells were infected at an MOI of 10 in the presence 
of 200ng/ml recombinant human IFN-γ (rhIFN-γ) (Pierce) for 4 hours.  After uptake, the cells were 
washed and fresh media with rhIFN-γ was added.  At 24 hours post-infection, the supernatant was 
removed from the infected monolayers and the cells were lysed with TRIzol.  TRIzol lysates were 
processed for RNA extraction.  RNA samples were reverse transcribed and Real-time PCR was 
performed using the Taq-Man sequence detection system with Absolute QPCR Mix (Applied 
Biosystems).  Values were calculated based on standard curves generated for each gene. 
Normalization of samples was determined by dividing copies of MHC class II mRNA by copies of 
18S rRNA.  18S probe (5’-TAMRA- CAAATTACCCACTCCCGACCG-3’) and primers F (5’-
GCTGCTGGCACCAGACTT-3’) and R (5’- CGGCTACCACATCCAAGG-3’); murine MHC 
class II (I-Ab) probe (5'-FAM-CGCAGCGCATACGATATGTGACCA-TAMRA-3') and primers 
Rev (5'-CTGTCGTAGCGCACGTACT-3') and For (5'-GGCGAGTGCTACTTCACCA-3'); 
human MHC class II (HLA-DRA) probe (5'-FAM-CTGGACCCTTTGCAAGAACCCTTCCC-
TAMRA-3') and primers F (5'-TCCAATGAACGGAGTATCTTGTGT-3') and R (5'-





The ∆secA2 mutant is attenuated in the murine low-dose aerosol infection model.  Previously, 
we demonstrated that an in-frame and unmarked ∆secA2 deletion mutant of M. tuberculosis is 
attenuated in mice following high-dose intravenous administration (10).  To better characterize the 
phenotype of the ∆secA2 mutant, we used a more natural low-dose aerosol exposure model 
infecting C57BL/6 mice with approximately 200 bacilli to the lungs, and included earlier time 
points than previously analyzed.  Following infection with the ∆secA2 mutant or the virulent M. 
tuberculosis parent H37Rv, groups of mice were sacrificed at times post-infection and the bacterial 
burden in the lungs, livers and spleens was enumerated by plating homogenates for colony forming 
units (CFU).    We observed a typical growth pattern for H37Rv in the lungs of the mice: 
significant growth during the early phase of infection followed by a period of persistence in which 
the number of bacilli remained constant over time (52) (Fig. 2.1A).  The transition between the 
growth and persistence phases correlates with the establishment of the TH1 response, a central 
feature of which is macrophage activation by IFN-γ (49, 52).  The ∆secA2 mutant was defective in 
the early growth phase of the infection when compared to H37Rv.  As early as nine days post-
infection, the ∆secA2 mutant had one log fewer bacilli in the lungs in comparison to H37Rv (Fig. 
2.1A).  This difference was maintained throughout the experiment, although both strains continued 
to grow to the day 16 time point.  We also observed fewer CFU for the ∆secA2 mutant in livers and 
spleens (0.5-1.0 log less) when compared to H37Rv (data not shown).  During the latter phase of 
infection, the ∆secA2 mutant resembled H37Rv in persisting although at the final 80 day time point 
the CFU burden in lungs of the ∆secA2 mutant infected mice had dropped slightly.  In addition to 
reduced bacillary load, mice infected with the ∆secA2 mutant exhibited an increase in length of 
survival (mean survival of 372 + 29 days) in comparison to mice infected with H37Rv (mean 





The ∆secA2 mutant has an attenuated phenotype in unactivated macrophages but not in 
activated macrophages.  The observed in vivo phenotype of the ∆secA2 mutant indicated a role 
for SecA2 in the early phase of infection, during which M. tuberculosis is growing in macrophages.  
We hypothesized that the ∆secA2 mutant is defective for growth in unactivated macrophages.  We 
tested this hypothesis by comparing the ability of the ∆secA2 mutant and H37Rv to replicate 
within unactivated bone marrow derived macrophages from C57BL/6 mice.  The macrophages 
were infected ex vivo, and after four hours uptake the monolayers were washed and fresh media 
added back.  The growth of each strain was evaluated over a five day period by plating 
macrophage lysates for viable CFU.  The ∆secA2 mutant showed diminished growth in the 
macrophages and displayed up to one log less CFU by Day 5 (Fig. 2.2A).  The intracellular growth 
defect of the ∆secA2 mutant was complemented by introduction of a wild-type copy of secA2 on 
an integrating plasmid, which indicated that the mutant phenotype was due to the absence of secA2 
(Fig. 2.2B).    
In contrast to unactivated macrophages which are permissive for M. tuberculosis growth, 
activated macrophages inhibit M. tuberculosis growth due to enhanced antimycobacterial activities 
(13, 21, 22).  We compared the ∆secA2 mutant and H37Rv in murine bone marrow derived 
macrophages activated by 24 hours pretreatment with recombinant murine IFN-γ (rmIFN-γ).  In 
the IFN-γ treated macrophages, H37Rv failed to grow but survived over time, and the ∆secA2 
mutant behaved similarly (Fig. 2.3A).  Infection of unactivated macrophages was performed in 




These results revealed a role for SecA2 in promoting M. tuberculosis growth in unactivated 
macrophages but no apparent role for SecA2 in M. tuberculosis survival in activated macrophages.  
They are consistent with the pattern of growth in vivo, where the ∆secA2 mutant exhibited reduced 
growth in the lungs of infected mice in the early growth phase of infection and then behaved 
similarly to H37Rv after the onset of the TH1 immune response and concomitant macrophage 
activation. 
 
The ∆secA2 mutant has an attenuated phenotype in oxidative burst deficient macrophages.  
We previously reported that the ∆secA2 mutant of M. tuberculosis is defective in secreting the 
antioxidant enzymes SodA and KatG (10).  M. tuberculosis is relatively resistant to ROI (13) 
which could be an important property for intracellular survival in the face of the macrophage 
oxidative burst, and the SecA2-dependent secreted SodA and KatG are among the M. tuberculosis 
molecules implicated in this resistance (67).  We tested whether the sole role of SecA2 in 
macrophage growth is to protect the bacillus from the oxidative burst during intracellular infection.  
Bone marrow derived macrophages from p47 phox-/-, gp91phox-/-, and C57BL/6 mice were prepared 
and infected in parallel with the ∆secA2 mutant or H37Rv.  These phox-/- mice lack different 
components of the phagocyte oxidase complex, which is responsible for the oxidative burst of 
macrophages (46).  In these oxidative burst deficient macrophages, the ∆secA2 mutant showed the 
same growth defect as observed in wild-type C57BL/6 macrophages (Fig. 2.4A and 2.4B).  This 
indicated that SecA2 contributes to intracellular growth even in the absence of an oxidative burst.  
Consequently, SecA2 must have a function in intracellular growth other than just protecting the 
bacillus from ROI generated during the oxidative burst.   
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As an independent assessment of the role of SecA2 in protecting against oxygen radicals, we 
compared in vitro sensitivity of the ∆secA2 mutant and H37Rv to a variety of ROI species.  
Among the compounds tested were pyrogallol and hypoxanthine/xanthine oxidase; both of these 
treatments generate extracellular superoxide.  Plumbagin (cytoplasmic superoxide generator), 
hydrogen peroxide, and cumene hydroperoxide were also tested.  In all cases, the ROI treatments 
showed an equivalent degree of killing for the ∆secA2 mutant and H37Rv (data not shown).   We 
further tested the strains for their sensitivity to other stresses including acid pH and heat shock and 
again saw no differences in killing.  The unaltered in vitro sensitivities of the ∆secA2 mutant in 
combination with the data from phox-/- macrophages suggested that the role of SecA2 in promoting 
growth in macrophages is not solely to protect the bacteria from damaging ROI and involves other 
mechanisms.  
 
Macrophages infected with the ∆secA2 mutant release higher levels of pro-inflammatory 
cytokines and RNI.  To determine if the SecA2-dependent secretion pathway contributes to M. 
tuberculosis inhibition of host immune responses, we compared cytokine production by 
macrophages infected with the ∆secA2 mutant or H37Rv.  Bone marrow derived macrophages 
from C57BL/6 mice were infected as before and 24 hours post-infection supernatants were assayed 
for cytokine production using the Cytometric Bead Assay (BD Biosciences).  Macrophages 
infected with the ∆secA2 mutant produced more TNF-α and IL-6 than those infected with H37Rv 
(Fig. 2.5), with an average difference of 2.5 fold for TNF-α and 3.5 fold for IL-6.  Introduction of 
an integrated plasmid expressing wild-type secA2 complemented the increased cytokine 




We also assayed production of RNI in the supernatants of infected macrophages using the Griess 
Reagent which measures nitrite, the oxidation product of nitric oxide.  Measurements were taken at 
48, 72 and 96 hours post-infection.   The macrophages infected with the ∆secA2 mutant produced 
more RNI at all time points compared to macrophages infected with H37Rv (Fig. 2.6A, data 
shown for 72 hours), with an average difference of 1.5 fold.  In the same experiments at 0, 4 and 
24 hours post-infection, we also measured the levels of ROI in the cells, and saw no differences in 
level of ROI between cells infected with the ∆secA2 mutant or H37Rv (data not shown).  We also 
tested the level of RNI production by infected cells pretreated with IFN-γ 24 hours prior to 
infection which upregulates RNI production.  As expected, there was an overall increase in RNI 
production in cells pretreated with IFN- γ compared to untreated cells.  At 24 hours post-infection 
macrophages infected with the ∆secA2 mutant again exhibited higher levels of RNI in the 
supernatant (Fig. 2.6B).  The increased RNI production observed following infection with the 
∆secA2 mutant in the absence and presence of IFN-γ was complemented by introduction of a wild-
type copy of secA2.   
It is important to note that in these experiments the number of CFU in macrophage lysates 
following the 4 hour infection period was equivalent for both strains.  The above results suggest 
that, in comparison to H37Rv, the ∆secA2 mutant is defective in the ability to inhibit macrophage 
production of immunostimulatory molecules.  The end result being more highly activated 
macrophages upon infection with the ∆secA2 mutant. 
 
The ∆secA2 mutant has an attenuated phenotype in NOS2-/- macrophages.  Given the 
antimycobacterial activity of RNI, we considered the possibility that the increased levels of RNI 
observed were alone responsible for the growth defect of the ∆secA2 mutant in macrophages.  To  
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test this idea, we examined the growth of the ∆secA2 mutant and H37Rv in unactivated 
macrophages from NOS2-/- mice, which lack the inducible nitric oxide synthase and are defective 
for the nitrosative burst (38).  The ∆secA2 mutant still exhibited a growth defect in NOS2-/- 
macrophages that was equivalent to the defect observed in macrophages from C57BL/6 mice (Fig. 
2.7).  This data indicated that the role of SecA2 in intracellular growth involves functions other 
than protecting against reactive nitrogen intermediates.   
 As was done for ROI, we also assayed in vitro sensitivity of the ∆secA2 mutant and H37Rv 
to NO generated by spermadine nonoate (SPER/NO).  Treatment with SPER/NO led to an 
equivalent degree of killing of ∆secA2 mutant and H37Rv (data not shown).  The in vitro 
sensitivity result taken together with the observed growth defect of the ∆secA2 mutant in NOS2-/- 
macrophages suggests that the role of SecA2 in intracellular growth is not solely to protect against 
RNI.  
 
The ∆secA2 mutant is associated with higher IFN-γ induced MHC class II expression.  
Having demonstrated that macrophages infected with the ∆secA2 mutant produced higher levels of 
cytokine and RNI in comparison to H37Rv infected macrophages, we set out to see if the 
inhibition of other macrophage responses was altered by the ∆secA2 mutation.   Multiple 
laboratories have demonstrated that M. tuberculosis inhibits the expression of several IFN-γ 
regulated genes of the host.  Among these genes are the IFN-γ induced MHC class II genes 
required for antigen presentation (43, 50, 53).  To test for a role of SecA2 in M. tuberculosis 
inhibition of IFN-γ responses, we employed two different systems previously used to study this 
IFN-γ inhibition: primary murine macrophages and the human monocytic cell line THP-1.  Murine 
bone marrow derived macrophages were pre-infected with the ∆secA2 mutant, H37Rv, or the  
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complemented strain at MOI 10 for 24 hours followed by stimulation with rmIFN-γ.  After 15 
hours of IFN-γ treatment, expression of MHC class II (IA-b) transcript was measured by 
quantitative Real Time PCR (qRT-PCR).  As expected, IFN-γ treatment of uninfected cells 
increased MHC class II transcript and H37Rv inhibited the IFN-γ induction of MHC class II.  In 
contrast, infection with the ∆secA2 mutant did not reduce the level of MHC class II to the same 
degree as H37Rv (Figure 2.8A).  This difference between the ∆secA2 mutant and H37Rv in the 
level of IFN-γ induced MHC class II was at least 2.0 fold greater with the ∆secA2 mutant in five 
separate experiments (p=0.008 by Mann-Whitney test).  Similar experiments were performed with 
human THP-1 cells.  In these experiments rhIFN-γ was added to the cells at the time of infection 
with either the ∆secA2 mutant, H37Rv, or complemented strain.  Expression of MHC class II 
(HLA-DR) transcript was measured by qRT-PCR on samples collected at 24 hours post-infection.  
Again, infection with the ∆secA2 mutant did not reduce the level of MHC class II to the same 
degree as H37Rv (Figure 2.8B).  This difference between the ∆secA2 mutant and H37Rv in the 
level of IFN-γ induced MHC class II was reproducible with the ∆secA2 mutant exhibiting an 
average 1.5 fold difference in HLA-DR transcript level over five independent experiments 
(p=0.00003 by Student’s t test).  The phenotypes of the ∆secA2 mutant in both murine 
macrophages and THP-1 cells were complemented by the introduction of a wild-type copy of 
secA2.  This data provided another example of SecA2 functioning in the process(es) of M. 






 The accessory secretion factor SecA2 contributes to M. tuberculosis virulence.  Here we 
showed, with a natural low-dose aerosol model of infection, that as early as nine days post-
infection the ∆secA2 mutant had a lower bacterial burden in the lungs of mice in comparison to the 
parental M. tuberculosis H37Rv.  The attenuated phenotype of the mutant occurred during the 
early growth phase of infection, when M. tuberculosis is primarily growing in unactivated 
macrophages.  Consistent with this result, we showed that the ∆secA2 mutant had a growth defect 
in unactivated murine bone marrow macrophages in comparison to H37Rv.  It should be noted that 
the ∆secA2 mutant does not display any significant growth defect when grown in broth media (10).  
In contrast to the phenotype in unactivated murine macrophages, the ∆secA2 mutant did not 
exhibit a phenotype in IFN-γ activated macrophages.  Our experiments in vitro with primary 
murine macrophages appear to reflect the phenotypes observed in vivo in the murine model of 
infection. 
Since SecA2 is an accessory secretion factor, the role of SecA2 could be the proper 
secretion or surface localization of M. tuberculosis proteins required for intracellular growth.  
Previously, we identified SodA and KatG as proteins whose secretion into culture media depends 
on SecA2 (10).   Since both of these proteins are antioxidants, we considered the simple hypothesis 
that SecA2 promotes detoxification of ROI and thereby protects the bacillus from the oxidative 
burst of macrophages to promote intracellular growth.  Macrophage generated ROI could have 
direct antimicrobial effects or indirect effects involving alterations in host cell signaling pathways 
(44, 69).  There is a precedent for exported superoxide dismutases contributing to virulence in 
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bacterial pathogens (5), and various experiments suggest roles for M. tuberculosis SodA, KatG, 
and a surface localized superoxide dismutase, SodC, in pathogenesis and protection against the 
oxidative burst of macrophages (17, 18, 41, 47, 54).  However, when we tested the ∆secA2 mutant 
in phox-/- macrophages, it exhibited a growth defect equivalent to that observed in wild-type 
C57BL/6 macrophages.  In addition, our efforts to detect altered in vitro sensitivity of the ∆secA2 
mutant to ROI species, including extracellularly generated superoxide, were unsuccessful.  Taken 
together, these experiments do not reveal a role for SecA2 in protecting against the oxidative burst 
and they indicate an alternate function of SecA2 in intracellular growth.   
Yet, we can not entirely rule out the possibility that SecA2 contributes to ROI resistance.  
A role in protecting against ROI in macrophages and in vitro could have been masked by the other 
function(s) of SecA2 in intracellular growth and/or redundant ROI resistance mechanisms of M. 
tuberculosis.  Furthermore, even in the absence of phagocyte oxidase there are still reactive 
oxygen species generated in the cell through mitochondrial electron transport.  Our experiments 
can not rule out the possibility that mitochondrial generated ROI contribute to the phenotypes of 
the ∆secA2 mutant. 
In our studies, we also assessed the role that SecA2 plays in modulating the immune 
response.  It is becoming evident that virulent M. tuberculosis inhibits innate and adaptive immune 
responses.  In regard to innate immune responses, M. tuberculosis has been shown to inhibit 
macrophage production of IL-12 in a co-infection assay (45).  In addition, there is an emerging 
trend that virulent M. tuberculosis strains elicit reduced levels of pro-inflammatory cytokines 
(including TNF-α and IL-6) and RNI from macrophages than less virulent M. tuberculosis strains.  
This phenomenon has been described for the hypervirulent HN878 strain of M. tuberculosis and 
the hypervirulent mce1 mutant of M. tuberculosis (42, 58, 65).  There are also reports of virulent M. 
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tuberculosis eliciting lower levels or activities of cytokine and RNI from macrophages than 
attenuated and avirulent mycobacteria (2, 7, 20, 26).  However, it must be noted that for TNF-α a 
correlation between increased mycobacterial virulence and reduced cytokine production has not 
been a universal finding (12, 19, 57, 66).  In regard to adaptive responses, M. tuberculosis inhibits 
macrophage responses to IFN-γ stimulation, such as the upregulation of MHC class II (25, 43, 50, 
53).  MHC class II and presentation of mycobacterial antigens to CD4+ T cells is an essential 
component of the adaptive immune response to M. tuberculosis (22).   
In this study, we found that macrophages infected with the ∆secA2 mutant produced 
significantly greater levels of TNF-α, IL-6 and RNI than macrophages infected with H37Rv.  This 
suggested a function for SecA2 in inhibiting the innate immune response.  We were unable to 
detect IL-12 production by our infected macrophages.  The increased level of IFN-γ induced MHC 
class II message observed with the ∆secA2 mutant versus H37Rv suggested an additional role for 
SecA2 in suppressing the adaptive immune response.  To our knowledge this is the first report of a 
M. tuberculosis mutant with a defect in the inhibition of IFN-γ responses.   
These immunomodulatory activities of SecA2 are likely important to M. tuberculosis 
virulence.   All of the host molecules we identified as being regulated by SecA2 are demonstrated 
to contribute to the control of tuberculosis in the mouse model.  Mice deficient in TNF-α, IL-6, 
NOS2, or CIITA (MHC class II transcriptional regulator) are all more permissive for M. 
tuberculosis infection as shown by increased bacterial burden in organs and decreased length of 
survival in comparison to infection of wild-type mice (6, 23, 39, 60, 62).  Immunosuppression by 
SecA2 may influence the course of M. tuberculosis infection in many ways including the 
establishment of a permissive environment for intracellular growth in macrophages and limiting 
antigen presentation in the host.  By infecting NOS2-/- macrophages with the ∆secA2 mutant, we 
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demonstrated that suppression of RNI was not the only important factor regulated by SecA2 for 
promoting intracellular growth.  We believe the attenuated phenotype of the ∆secA2 mutant in 
macrophages and mice is a reflection of an imbalance in multiple cytokines and effector 
mechanisms, possibly including molecules we have yet to identify. 
Interestingly, all four of the molecules we found upregulated by macrophages infected with 
the ∆secA2 mutant are associated with Toll like receptor 2 (TLR2) and Myeloid differentiation 
factor 88 (MyD88) signaling pathways in host cells.   To varying degrees TNF-α, IL-6 and RNI 
are induced by mycobacterial stimulation of TLR2-dependent MyD88-dependent pathways (11, 30, 
32, 48, 59, 63, 64, 70).  Thus, an increased ability of the ∆secA2 mutant to signal through TLR2-
MyD88-dependent pathways could account for the increased macrophage responses.  However, 
there are alternate explanations given the complexities of cell signaling.  Interestingly, there is also 
a role for TLR2 in the process of M. tuberculosis inhibition of IFN-γ induced MHC class II (25, 27, 
51).  However, our observation that infection with the ∆secA2 mutant led to higher IFN-γ induced 
MHC class II message than infection with H37Rv is opposite to what would be predicted by 
increased TLR2 signaling.  TLR2-independent pathways of M. tuberculosis inhibition of IFN-γ 
responses have also been identified in which SecA2 could be involved (25, 55).  Alternatively, 
increased TNF-α levels generated by the ∆secA2 mutant could synergize with IFN-γ to promote 
the observed increase in MHC class II (71).   
Modification of the immune response is a strategy used by other bacterial pathogens to 
survive in the host, and the bacterial factors involved are often secreted and surface proteins 
localized by specialized secretion systems (14).  Currently, there are two known specialized 
secretion systems in M. tuberculosis: the SecA2-dependent system and the ESAT-6/Snm system 
(36).  Interestingly, the ESAT-6/Snm system which localizes the small ESAT-6 and CFP-10 
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proteins has also been reported to contribute to immunosuppression (37, 68).  M. tuberculosis 
mutants lacking the snm4 (Rv3877) and snm9 (Rv3615c) components of the ESAT-6 system elicit 
increased levels of TNF-α, RNI and IL-12 by macrophages.  Further, M. tuberculosis snm mutants 
exhibit a growth defect in unactivated macrophages and an early growth phenotype in mice (24, 29, 
31, 37, 68).  There is no immediate explanation for the similarity in snm and ∆secA2 mutant 
phenotypes, since the ∆secA2 mutant secretes ESAT-6 (data not shown).   
Because SecA2 is a secretion factor, its role in immunomodulation is most likely related to 
proper secretion or cell wall localization of an immunosuppressive factor.  However, all of the 
proteins localized by SecA2, particularly cell wall proteins, are not yet known.  The mycobacterial 
cell wall is a complex structure that contains many diverse molecules with reported 
immunomodulatory properties (33).   These include several surface molecules reported to 
influence the production of inflammatory TNF-α, IL-6 and/or RNI such as surface lipoproteins, 
lipoarabinomannan (LAM) and its precursor lipomannan (LM), phthiocerol dimycocerosates 
(PDIMs or DIMs), and modified trehalose dimycolate (1, 3, 11, 15, 35, 55-57, 61).  The increased 
immune response elicited  by the ∆secA2 mutant could be explained by different amounts of 
immunoregulatory molecules in the cell wall or an altered cell wall structure with greater exposure 
of stimulatory molecules that interact with host receptors, such as TLR2.  Thus, we are considering 
the possibility that the immunosuppressive effect of SecA2 is due to a role in localization of cell 
wall synthetic enzymes that influence cell wall architecture.  A final possibility is that the ∆secA2 
mutant phenotypes actually represent increased release of a stimulatory molecule (10). Future 
efforts will be aimed at identifying the SecA2-dependent factors that suppress innate and adaptive 
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SecA2 is an accessory secretion factor of M. tuberculosis involved in the export 
of a subset of proteins.  A ∆secA2 mutant of M. tuberculosis is attenuated for growth in 
non-activated murine bone marrow derived macrophages and in the early stages of 
murine infection.  Macrophages infected with the ∆secA2 mutant produce increased 
levels of TNF-α, IL-6 and RNI compared to those infected with the wild type.  These 
host factors are known to be induced by M. tuberculosis via the host adaptor protein 
MyD88, an integral component of the TLR pathway, and they were all shown to function 
in  host control of M. tuberculosis.  The more robust cytokine responses induced by the 
∆secA2 mutant suggests that the role of SecA2 is to promote virulence of M. tuberculosis 
by dampening the immune response.  Given that the altered responses we observed are 
controlled by MyD88, we hypothesized that MyD88 would have a critical role in 
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controlling the growth of the ∆secA2 mutant.   We directly tested this hypothesis by 
comparing the growth of the ∆secA2 mutant in macrophages derived from wild type 
C57BL/6 mice in parallel with cells derived from MyD88 deficient mice (MyD88-/-).   
We observed that MyD88 is important for the attenuation of the ∆secA2 mutant, by 
demonstrating that the ∆secA2 mutant grows to wild type levels in MyD88-/-
macrophages, but not in C57BL/6 macrophages.  This supports the hypothesis that 
increased MyD88 responses can control intracellular growth of the ∆secA2 mutant.  More 
importantly, this suggests that MyD88 responses have potential to control M. 
tuberculosis, but that virulent M. tuberculosis evades this protective response.  TNF-α is 
an important host factor in controlling mycobacterial infection, and cells infected with the 
∆secA2 mutant produce more of this proinflammatory cytokine.  We hypothesized that 
the antimycobacterial effects mediated by MyD88 may depend on TNF-α.  Consistent 
with that notion, we observed that TNF-α also contributes to the intracellular growth 
inhibition of the ∆secA2 mutant, as the mutant grows to wild type levels in TNF-α-/-
 macrophages.  TNF-α induction of cytotoxicity via apoptosis of host cells has been 
described as a mechanism to inhibit the growth of M. tuberculosis.  However, we found 
that the ∆secA2 mutant induced less overall cytotoxicity than the wild type during 
macrophage infection. Therefore, cytotoxicity does not account for the attenuated 
phenotype.  This data, in combination with our previously published data, demonstrates 
that there is a MyD88/TNF-α dependent growth inhibition of the ∆secA2 mutant that is 
independent of RNI/ROI/cytotoxicity.  We believe this represents a novel mechanism for 





 Mycobacterium tuberculosis, like many other successful human pathogens, has a 
complex relationship with the host immune response.   M. tuberculosis needs host cells, 
notably the immune effector cells macrophages and dendritic cells, as sites for 
replication.  The bacterium protects itself within these cells from the deleterious effects of 
the host response, which include the acidification of the phagosomal compartment and 
maturation of the phagosome, production of reactive nitrogen intermediates (RNI), and 
production of reactive oxygen intermediates (ROI).  M. tuberculosis also down modulates 
several of the host mechanisms that drive the adaptive response, including the 
upregulation of MHC class I and class II molecules.  Some of the M. tuberculosis factors 
that contribute to the host immune modulation have been found, and yet still many 
remain undiscovered.   
 The arsenal of cytokines and immune effector molecules that the host employs 
against Mycobacterium tuberculosis is diverse.  TNF-α and INF-γ are two of the most 
important cytokines contributing to the host response against M. tuberculosis.   Mice 
deficient in either of these cytokines do not mount an effective adaptive response or form 
granulomas.  The bacteria replicate uncontrollably and mice succumb to disease rapidly 
(6, 11, 30, 31). 
 While the role that TNF-α plays in the control of an M. tuberculosis infection in 
the whole animal model is undisputable, the exact mechanisms by which TNF-α controls 
growth of the bacteria in the host is complex and not fully understood.  How TNF-
α affects  M. tuberculosis in a cell autonomous system is a complicated story, and reports 
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range from TNF-α inhibiting the growth of M. tuberculosis in cultured macrophages to 
promoting intracellular growth (7, 17, 21 , 25, 44, 66).  In the reports where TNF-α 
promotes intracellular killing of mycobacteria, the exact mechanism is still also yet to be 
determined.  TNF-α has been shown to stimulate iNOS and growth inhibition of 
mycobacteria by iNOS dependent mechanisms.  In addition, TNF-α dependent, iNOS 
independent mechanisms have also been described (7, 19, 29).  One proposed TNF-α 
dependent, iNOS independent mechanism of growth inhibition is via induction of 
cytotoxicity by apoptosis.  It is proposed that TNF-α promotes apoptosis and that the 
intracellular replication of mycobacteria can be inhibited by apoptosis (32, 40, 52, 55). 
Avirulent strains of M. tuberculosis have been shown to induce higher levels of apoptosis 
than virulent strains, by a mechanism linked by several groups to the levels of bioactive 
TNF-α, although this has not been a universal finding (1, 5, 22, 40, 41, 56, 59, 63, 64, 73, 
74).  However, it is likely that other mechanisms of TNF-α growth inhibition also exist. 
 The innate host response, including the induction of TNF-α, is controlled by a 
complex network of signaling molecules.  An important innate signaling pathway is the 
Toll-like receptor (TLR) response pathway (18).  There are eleven described TLR surface 
receptors, which recognize a variety of pathogen associated molecular patterns (PAMPs).  
Once engaged, the TLRs signal through a series of intracellular adaptor proteins, 
including MyD88 (18).  MyD88 is a central signaling component of all TLR, with the 
exception of TLR3.  TLR2, TLR4, TLR9 and MyD88 have all been implicated in the host 
response to M. tuberculosis (reviewed by Jo et al, (38)).  Mice with deficiencies in TLR2, 
TLR4, TLR9 or MyD88 show varying degrees of increased susceptibility to M. 
tuberculosis infection, with MyD88 showing the most dramatically increased 
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susceptibility, demonstrating the importance of these innate signaling molecules in the 
host response against M. tuberculosis (2, 4, 12, 23, 27, 34, 36, 39, 54, 62, 65, 67, 70, 79, 
80).  There is an ever growing list of mycobacterial factors that engage the receptors of 
the TLR pathway, including an array of lipids, lipoproteins, and proteins (38).  
Significant to our studies, the host induction of IL-6, RNI and TNF-α in response to M. 
tuberculosis have all been linked to signaling through TLR via MyD88 (15, 36, 37, 54, 
62, 68, 70, 81). 
 The ∆secA2 mutant of M. tuberculosis is attenuated for growth in a murine model 
of infection during the first three weeks of infection, a time during which mycobacteria 
are replicating in macrophages (14, 46).  Supporting this, a ∆secA2 mutant is also 
attenuated for growth in non-activated macrophages (46).  The macrophages infected 
with the ∆secA2 mutant have a more robust innate immune response to infection 
compared to those infected with the wild type strain, and produce increased levels of 
TNF-α, IL-6 and RNI (46).  These cytokines all have a demonstrated role in controlling 
M. tuberculosis in a murine model (31, 47, 51).  As described, these proinflammatory 
molecules have all been shown to be triggered by signaling through MyD88.  Given the 
importance of these cytokines to the host immune response against M. tuberculosis and 
the central role that MyD88 plays in controlling these responses, we sought to investigate 
the role of MyD88 in controlling the growth of the ∆secA2 mutant.   In addition, given 
the potential for TNF-α to be an antimycobacterial effector, we also sought to determine 
the role this cytokine plays in attenuating the growth of the mutant.  We tested the 
∆secA2 mutant for growth in macrophages from both MyD88 and TNF-α deficient mice 
and showed that both of these host immune regulators had an antimicrobial effect on the 
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∆secA2 mutant.  This suggests that there are MyD88/TNF-α dependent antimicrobial 
mechanisms against M. tuberculosis, but that wild type M. tuberculosis is able to combat 
these host effectors through the actions of SecA2. 
 
Materials and Methods 
 
Bacterial Strains and Growth Conditions 
The Mycobacterium tuberculosis strains used in this study H37Rv, mc23112 (∆secA2 
mutant, stock derived from a single colony), H37Ra (ATCC 25177 ), (13) were grown in 
Middlebrook 7H9 broth (Difco) with 0.2% glycerol, 1X ADS (albumin dextrose saline) 
and 0.05% Tween 80 (Tw).  When appropriate, the media was supplemented with the 
antibiotic hygromycin (50µg/ml). 
 
Animals 
Female C57BL/6 mice were purchased from Charles River Laboratories.  The MyD88-/- 
mice were a kind gift of Dr.  Shizuo Akira (Osaka University, Osaka, Japan), Dr. Mark 
Heise (University of North Carolina, Chapel Hill, USA), and Dr. Stephen Clarke 
(University of North Carolina, Chapel Hill, USA) and were generated and maintained as 
described previously (3).  These mice were backcrossed ten times on a C57BL/6 
background.  TNF-α -/- mice were a kind gift from Dr. Jonathon Sedgwick (Eli Lilly and 
Co., Indianapolis, USA) and Dr. Jenny P.Y. Ting (University of North Carolina, Chapel 
Hill, USA) were generated and maintained as described previously (45).  These mice 
were generated using direct gene targeting of C57BL/6 embryonic stem cells (45)..  All 
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mice were housed in sterile microbarrier cages and were given autoclaved food and water 
ad libitum.   
 
Macrophage Infections 
Bone marrow derived macrophages were prepared from C57BL/6, MyD88-/-and TNF-α-/- 
mice as follows.  Mice were sacrificed by CO2 asphyxiation and the femurs were 
removed.  The cells were flushed out of the femurs using supplemented DMEM (Sigma) 
containing 10% heat-inactivated fetal bovine serum (HI-FBS), 2mM glutamine and 1X 
non-essential amino acids (NEAA).  Cells were washed twice and cultured in 
supplemented DMEM for 6 days in the presence of 20% L929 conditioned medium 
(LCM).  After 6 days, the cells were detached using 5mM EDTA (in PBS), washed twice 
with supplemented DMEM, and resuspended in supplemented DMEM with 10% LCM.  
The cells were then seeded into the wells of either an 8-well chamber slide (2 x 105 
macrophages/well), or a 24-well plate (8 x 105 macrophages/well) and were allowed to 
adhere overnight before infection.  In some experiments, the macrophages were 
pretreated for 24 hours with 10ng/ml recombinant murine ΙFN-γ (rmΙFN-γ) (Chemicon) 
before infection.    M. tuberculosis strains were taken from mid-log growth phase and 
washed one time in PBS 0.05%Tw.  Cells were resuspended in PBS-Tw and further 
diluted to the appropriate CFU/ml in supplemented DMEM.   The bacteria were added at 
the appropriate concentration to the cell monolayers to achieve a multiplicity of infection 
(MOI) of 1 or 10.  Macrophages were infected for 4 hours, at which time the monolayers 
were washed three times with supplemented DMEM to remove any non-cell associated 
bacteria, and then fresh media with 10% LCM was added back.  At various timepoints, 
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the media was removed from the wells and the cells were lysed with 0.1% Tween 80 and 
vigorous pipetting.  Lysates were diluted in PBS-Tw and plated onto 7H10 ADS glycerol 
0.05% Tw plates for enumeration of CFU. 
 
RNI measurements 
To measure RNI we used the Griess Reagent (Molecular Probes) and followed the 
manufacturer’s protocol.  Briefly, supernatants from infected macrophage monolayers 
were filter- sterilized twice using a 0.2µm low-protein binding filter, and mixed 1:1 with 
Griess reagent.  Samples were measured at 548nm, and the values converted to µM nitrite 
using a standard curve generated with sodium nitrite. 
 
TNF-α ELISA 
Infections were performed as described above using differentiated murine bone marrow 
derived macrophages.  Supernatants were harvested at 24hr and 96hr post-infection, 
double filtered using a 0.2µm filter to remove any bacteria and cell debris, and frozen at -
80oC until use.  TNF-α levels were measured using the BD OptEIA murine TNF ELISA 
kit (Becton Dickinson) as described by the manufacturer’s protocol. 
 
Lactate dehydrogenase (LDH) Assay 
Murine bone marrow derived macrophages infections were performed as described above 
at MOI=1 and supernatants harvested at 24hrs and 96hrs post-infection.  Maximal cell 
death and LDH release is determined by making a lysate from a control set of uninfected 
cells using 0.1% Tween 80.  LDH levels in the supernatants were determined using the 
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CytoTox 96 kit from Promega.  The values obtained from the unknown samples were 




The ∆secA2 mutant induces a more robust cytokine response that is sustained 
during the course of macrophage infection.  We previously demonstrated that the 
∆secA2 mutant of M. tuberculosis is defective for growth in non-activated murine bone 
marrow derived macrophages (46).  Concomitant with the growth defect, macrophages 
infected with the ∆secA2 mutant produce increased levels of the proinflammatory 
cytokines TNF-α, IL-6, and increased production of reactive nitrogen intermediates 
(RNI) compared to macrophages infected with the parental wild type H37Rv (46).  Our 
previous cytokine measurements were done at 24hrs post-infection, so we sought to 
determine if the more robust macrophage responses induced by the ∆secA2 mutant are 
transient, or if the macrophages maintain heightened cytokine production.  We measured 
cytokine levels at 24hrs as before, and also measured levels at 96hrs post-infection.  At 
96hrs, the macrophages infected with the ∆secA2 mutant are still showing a comparably 
heightened level of TNF-α production as compared to 24hrs post-infection, as shown in a 
representative of four individual experiments (p ≤ 0.001 at 24hrs and 96hrs by Student’s t 
test) (Fig. 3.1).  We were unable to test the complemented strain in these experiments, but 
have previously demonstrated that the increased cytokine production induced by the 
∆secA2 mutant can be complemented by the addition of a wild type copy of secA2 (46).  
We also saw a similar sustained response at 96hrs for RNI production (data not shown).  
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This demonstrates that the elevated levels of TNF-α and RNI induced by the ∆secA2 
mutant are sustained throughout the course of the infection.  We also tested for IL-6 
production at 96hrs, but saw inconsistent results in the ability of the mutant to induce a 
 sustained increase in IL-6 production versus cells infected with the wild type strain.  We 
can not explain this discrepancy.   
 
MyD88 dependent antimicrobial responses control the growth of the ∆secA2 
mutant.  MyD88 is an integral signaling adaptor in the TLR pathway.  Molecules from 
mycobacterium signal through TLRs and MyD88 to induce TNF-α, IL-6 and RNI 
(Reviewed in (38)).  These cytokines all have a demonstrated role in controlling M. 
tuberculosis in a murine model (31, 47, 51).  The macrophages infected with the ∆secA2 
mutant have a more robust immune response to infection compared to those infected with 
the wild type strain, and produce increased levels of TNF-α, IL-6 and RNI (46).  Given 
the importance of these cytokines to the host immune response against M. tuberculosis 
and the central role that MyD88 plays in controlling these responses, we sought to 
investigate the role of MyD88 in inhibiting the growth of the ∆secA2 mutant.   We 
compared growth of H37Rv and the ∆secA2 mutant in macrophages derived from mice 
deficient in MyD88 (3).  Bone marrow derived macrophages from MyD88-/- mice and the 
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 corresponding wild type C57BL/6 mice were prepared and infected in parallel with the 
∆secA2 mutant or H37Rv.  As we had demonstrated previously, the ∆secA2 mutant was 
attenuated for growth in C57BL/6 macrophages, presented as the average of six 
independent experiments each performed with triplicate samples for each strain (p= 
0.001) (Fig. 3.2).  In stark contrast, the ∆secA2 mutant replicated in the MyD88-/- 
macrophages and was no longer statistically different from the wild type (p=0.09 vs 
H37Rv).  The mutant grew four-fold over five days in the MyD88-/- macrophages, 
compared to no growth observed for the mutant in C57BL/6 macrophages (p=0.002).  
The wild type itself displayed an equivalent growth pattern in both C57BL/6 and MyD88-
/- macrophages (p= 0.45).   
 
Characterization of the attenuated strain H37Ra.  In the literature, there are reports of 
other attenuated mutants of M. tuberculosis that also induce increased levels of 
proinflammatory cytokines, such as mutants in ESAT-6 or the ESAT-6 secretion system 
(50, 75).  These data raise the question whether there is induction of a more robust 
immune response to certain mutants of M. tuberculosis, or whether it is a general 
property of all attenuated mutants. Supporting the idea that it is not a general phenotype 
of all mutants, there is a report that the pca mutant of M. tuberculosis is attenuated, and 
yet does not induce increased levels of TNF-α (61).  In fact, the attenuated pca mutant 
induces lower levels of cytokines compared to its parental wild type strain (61).  Mutants 
in the acid induced operon Rv3083-Rv3089 of M. tuberculosis are also attenuated, yet 
induce lower levels of cytokines, including IL-6, than the parental wild type (20).  These 
reports demonstrate that there is complexity to the host cytokine response to M.  
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tuberculosis and that there does not seem to be a universal correlation between the levels 
of TNF-α and the growth outcome of a particular strain. 
H37Ra is an attenuated strain of M. tuberculosis used by many research groups to 
study the immunology of M. tuberculosis infection.  H37Ra, like our parental wild type 
strain H37Rv, was generated from the classical M. tuberculosis strain H37, and H37Ra 
was attenuated through multiple passages on culture media (76, 77).  While several 
studies have been undertaken to determine the loci in H37Ra that are responsible for the 
attenuation, the full extent of the contributing mutations still remain to be elucidated (16, 
35, 49, 57).  Several groups have reported that this strain induces increased levels of 
TNF-α compared to the wild type H37Rv; however, this finding has not been universal 
(5, 26, 33, 40, 71).  Discrepancies in these reports could be due to differences in 
experimental design.  We compared H37Ra to the ∆secA2 mutant and H37Rv for its 
ability to induce TNF-α in non-activated murine bone marrow derived macrophages in 
our experimental system.  As demonstrated previously, the ∆secA2 mutant induced an 
increased level of TNF-α compared to parental H37Rv (p= 0.001) (Fig.3.3).  H37Ra 
induced heightened macrophage responses in our system, inducing two fold more TNF-α 
than wild type (p=0.0006), and even exhibited increased levels of TNF-α compared to the 
∆secA2 mutant (p=0.003).   
These data demonstrated that like the ∆secA2 mutant, H37Ra also induces a more 
robust TNF-α response.  As will be discussed in Chapter 4, H37Ra has an altered colony 
morphology on plates similar to that of the ∆secA2 mutant.   Given the similarities 
between these two strains, and the fact that the strain background of H37Ra and its  
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mutations are largely uncharacterized, we sought to determine if there were any 
alterations in secA2 in H37Ra.  We sequenced the secA2 gene of H37Ra to ensure that 
there were no mutations, and found the H37Ra sequence to be identical to H37Rv (data 
not shown).  We also performed a Western blot analysis to confirm expression of SecA2 
in H37Ra and observed production of SecA2 under standard growth conditions (N. Rigel, 
data not shown).  This confirmed that phenotypes observed with H37Ra were not due to 
secA2 mutations.  This data demonstrated that in our cell autonomous system, H37Ra is 
another attenuated mutant of M. tuberculosis that induces a more robust immune 
response.  We will use this strain to assess the specificity of the ∆secA2 mutant 
phenotypes below. 
 
H37Ra is attenuated even in the absence of MyD88.  Given that H37Ra, like ∆secA2 
mutant, induces a more robust immune response, we sought to compare the role of 
MyD88 in the attenuation of this strain.   For this reason, we compared the growth H37Ra  
in parallel to wild type H37Rv and the ∆secA2 mutant in C57BL/6 and MyD88-/- 
macrophages, in a set of three independent experiments.  As we had seen, the wild type 
replicated to a similar level in C57BL/6 and MyD88-/- macrophages, and the  ∆secA2 
mutant was attenuated in the C57BL/6 macrophages and not in the MyD88-/- 
macrophages (Fig 3.4, data not shown).  H37Ra was attenuated for growth in the 
C57BL/6 macrophages compared to wild type (p=0.0008 for Day 5).  In contrast to the 
 ∆secA2 mutant, H37Ra was as attenuated in the MyD88-/- macrophages as it was in the 
C57BL/6 macrophages and showed no statistical growth difference in the two types of 




MyD88-/- cells have been shown to have diminished phagocytosis, however, this 
has not been a universal finding with all bacteria (9, 10, 24, 72).  We confirmed that after 
the bacterial uptake period of our infection, there were equivalent numbers of bacteria in 
the MyD88-/- macrophages and in C57BL/6 macrophages (p ≥ 0.05) (Fig. 3.2 and Fig. 
3.4), and that equivalent numbers of cells were infected (data not shown).  In our system, 
there does not seem to be any phagocytosis impairment in the MyD88-/- macrophages. 
Taken together, these data show that the attenuation of the ∆secA2 mutant is due 
to a MyD88-dependent antimicrobial response, but that these cells are not permissive for 
the growth of any attenuated strain.  To our knowledge, this exciting result represents the 
first example of MyD88 dependent antimicrobial response against M. tuberculosis in a 
cell autonomous system. 
 As we have mentioned previously, published studies demonstrate that the 
production of M. tuberculosis induced immune effectors, such as TNF-α, IL-6 and RNI is 
dependent on MyD88.  Our hypothesis is that the ∆secA2 mutant is able to grow in 
MyD88-/- macrophage due to the lack of a MyD88 directed response.   We tested in our 
system the possibility that M. tuberculosis induction of TNF-α and RNI were MyD88 
dependent.  We examined the production of TNF-α in macrophages derived from wild 
type C57BL/6 and MyD88-/- mice when uninfected, or infected with the wild type H37Rv 
or ∆secA2 mutant.  As we had seen previously, the ∆secA2 mutant induced increased 
levels of TNF-α in C57BL/6 macrophages when compared to H37Rv (p=0.003) (Fig. 
3.5).  In contrast to C57BL/6 macrophages, the MyD88-/- cells were unable to produce  
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detectable levels of TNF-α when infected with either strain (Fig. 3.5).  RNI levels were 
also undetectable in the infected MyD88-/- macrophages (data not shown).  We also 
observed similar results for RNI production being dependent on MyD88 (data not 
shown).  We did not measure IL-6 levels, but expect that IL-6 production in infected cells 
would have also been dependent on MyD88.   
 
TNF-α plays a role in the attenuation of the ∆secA2 mutant.  TNF-α is an important 
proinflammatory molecule that has pleiotropic effects over many signaling pathways 
within the host (78).  While the importance of TNF-α in controlling M. tuberculosis 
infection in the whole animal model is clear, the exact role that TNF-α plays in 
controlling M. tuberculosis in a cell autonomous system is still undetermined.  When 
used in synergy with IFN-γ, TNF-α exerts antimicrobial activity against mycobacteria, 
which is  mediated by RNI (7, 19, 28).  Although, when TNF-α alone is used to stimulate 
macrophages, its role in antimicrobial defense is not as clear.   
Given the increase of TNF-α during infection with the ∆secA2 mutant, we tested 
the role of this cytokine in the attenuation of the mutant.  We infected macrophages 
derived from TNF-α-/- mice and the corresponding wild type C57BL/6 mice in parallel in 
five independent experiments.  In our system, we saw that the wild type displayed similar 
growth kinetics in macrophages from both mice (Fig. 3.6).  The growth of the wild type 
is somewhat elevated at Day 5 in the TNF-α-/- cells, however it is not statistically 
different (p=0.13).  When we examined the growth of the ∆secA2 mutant, it again 
showed attenuation in C57BL/6 macrophages at Day 3 and Day 5 post-infection (p ≤  
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0.008).  In contrast, the mutant grew to the same levels as wild type in the TNF-α-/- 
macrophages, and demonstrated increased levels of growth at Day 3 and Day 5 compared 
to ∆secA2 mutant in C57BL/6 macrophages (p≤ 0.03).  The mutant showed no statistical 
difference from the wild type in TNF-α-/- cells at Day 3 or Day 5 (p ≥ 0.15).  This data 
demonstrates that a TNF-α dependent host response is required for the attenuation of the 
∆secA2 mutant.  In our system, TNF-α has an antimicrobial against M. tuberculosis that 
that is able to inhibit the growth of the ∆secA2 mutant.  Wild type M. tuberculosis can 
resist this antimicrobial mechanism in a SecA2 dependent manner. 
 
TNF-α-/- macrophages are deficient in the production of immune effectors.  We have 
demonstrated that TNF-α mediates an antimicrobial response against the ∆secA2 mutant 
using macrophages from TNF-α-/- mice.  As described, TNF-α is a potent host signaling 
molecule, and one of the known effectors modulated by TNF-α is RNI (7, 19, 29).  We 
sought to confirm that there was an abrogation of TNF-α dependent responses in the 
TNF-α-/- macrophages, by measuring levels of RNI.  We measured RNI production in 
macrophages derived from TNF-α-/- mice and compared the levels to those induced in 
C57BL/6 macrophages.  When non-activated macrophages were infected with either the 
wild type or ∆secA2 mutant at MOI of 10, we saw that the levels of RNI in TNF-α-/- 
macrophages are reduced below the level of detection, compared to those measured in 
C57BL/6 macrophages (Fig. 3.7A).  This is in agreement with published data that TNF-α 
is required RNI production (7, 19).  We saw that the ∆secA2 mutant induces increased 
levels of RNI in untreated C57BL/6 macrophages as we have described previously (p ≤  
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0.02) (46).  When macrophages from TNF-α-/- or C57BL/6 mice were treated with IFN-γ, 
we again saw that there were overall lower levels of RNI produced in the TNF-α-/- 
macrophages (Fig. 3.7B).   We also saw that the ∆secA2 mutant induced increased levels 
of RNI compared to the wild type strain in both IFN-γ treated C57BL/6 and TNF-α-/- 
macrophages (p ≤ 0.02)  (Fig. 3.7B).  This data demonstrated that in IFN-γ treated cells, 
the increased RNI production observed with the mutant is not dependent on TNF-α, since 
the difference between the wild type and mutant is still present in the TNF-α-/- 
macrophages.  This supports the idea that increased RNI production observed in the 
presence of the ∆secA2 mutant is due to increased TLR signaling, and not to a 
downstream effect of  increased TNF-α.  Overall, this data confirmed that in our 
experimental system, there is an abrogration of TNF-α dependent host effectors in the 
TNF-α-/- macrophages, by measuring one such effector RNI.  However, our previous data 
demonstrates that the ∆secA2 mutant is equally attenuated in non-activated murine bone 
marrow derived macrophages from wild type and iNOS-/- mice (46).  Therefore, we 
hypothesize that the TNF-α-/- macrophages are deficient in an as yet undetermined host 
factor that controls the growth of the ∆secA2 mutant.  Alternatively, TNF-α may function 
to activate an effector, and the TNF-α-/- macrophages are defective for this activation. 
 
The ∆secA2 mutant triggers less cell death than wild type M. tuberculosis.  What is 
the TNF-α dependent, RNI independent antimicrobial effector mechanism?  As 
described, there are reports that some attenuated strains of M. tuberculosis induce more 
apoptosis than virulent strains, and that the induction of apoptosis may be a TNF-
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α dependent antimicrobial mechanism against M. tuberculosis (32, 40, 52, 55).  We 
sought to investigate if the TNF-α dependent antimicrobial mechanism contributing to 
the attenuation of the ∆secA2 mutant was via host cell death.  We measured levels of 
LDH release at 24hrs and 96 hrs post-infection as a marker of host cell death (43, 48).  
During the course of the experiment, we saw an increase in cytotoxicity under all 
conditions at 96hrs versus 24hrs (Fig. 3.8).  At 24hrs, we saw a decrease in cell death in 
the wild type infected cells compared with uninfected.  There was no difference in the 
level of cell death measured between the uninfected cells or wild type infected cells at 
96hrs.  In the cells infected with the ∆secA2 mutant, there was less cell death at both 
timepoints than in uninfected cells (p≤0.01).   The ∆secA2 mutant also induced less cell 
death than H37Rv at both timepoints (p≤0.002 at 96hrs).  We also measured cell death 
using the redox dye Alamar Blue (Invitrogen), and again saw that ∆secA2 mutant induced 
less cell death than wild type H37Rv (J. McCann, data not shown). This data 
demonstrates that ∆secA2 mutant does not cause increased levels of host cell death.  The 
host mechanism acting to inhibit the growth of the ∆secA2 mutant must be independent 
of host cytotoxicity. 
Taken together, our data demonstrates a role for MyD88 in the production of an 
antimicrobial response against the ∆secA2 mutant M. tuberculosis in our cell autonomous 
system.  TNF-α, a MyD88 dependent host effector, is also involved in the antimicrobial 
effect controlling the ∆secA2 mutant.  Give our previously published results, in 
conjunction with data presented in this report, we propose the existence of a novel 
antimicrobial host response against M. tuberculosis, which is acting to control the growth 
of the ∆secA2 mutant.  This novel defense mechanism is dependent on MyD88 and TNF- 
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α, yet independent of RNI, ROI, or host cell death.  We believe that SecA2 plays a role in 




 We previously demonstrated that the accessory secretion factor SecA2 contributes 
to the virulence of M. tuberculosis (46).  We previously tested the role for RNI and ROI 
in non-activated macrophages in controlling the growth of the ∆secA2 mutant, and found 
that the ∆secA2 mutant was still attenuated in the absence of these effectors (46).  This 
indicates that there is an ROI/RNI independent host mechanism controlling the growth of 
the ∆secA2 mutant.   Macrophages infected with the ∆secA2 mutant produce a more 
robust host immune response compared to that elicited by the wild type H37Rv, including 
elevated levels of TNF-α, IL-6 and RNI (46).    We hypothesized that the role of SecA2 
was to modulate the host immune response, and that the immune disregulation was 
responsible for the attenuation of the mutant.  As described, the elevated host molecules 
that we identified have all been linked to signaling by the host adaptor MyD88.  We 
hypothesized that the altered macrophage responses controlled by MyD88 were 
contributing to the attenuation of the ∆secA2 mutant.   In this work we tested this 
hypothesis, by comparing the growth of the ∆secA2 mutant in macrophages from wild 
type C57BL/6 mice and in MyD88-/- mice.  The ∆secA2 mutant of M. tuberculosis is 
attenuated for growth in wild type C57BL/6 macrophages.  However, the ∆secA2 mutant 
replicates to wild type levels in MyD88 deficient macrophages.  This suggests that there 
 101
is a MyD88 dependent antimicrobial response against M. tuberculosis, that the ∆secA2 
mutant is sensitive to the effects, and that wild type H37Rv is relatively resistant. 
MyD88 is an indispensable component of the host immune response to M. 
tuberculosis.  Mice deficient in this adaptor protein are unable to control the replication 
of M. tuberculosis and rapidly succumb to disease within 30-40 days, although one report 
said that MyD88 played a lesser role (34, 67, 68, 79).  Surprisingly, there has been no 
reported role for antimicrobial MyD88 in a cell autonomous macrophage infection model.  
One previous report demonstrates that wild type M. tuberculosis displays similar growth 
kinetics in macrophages from C57BL/6 mice and MyD88-/- mice (69). This is consistent 
with our model that wild type M. tuberculosis is resistant to effects mediated by MyD88, 
as it grows equally well in the presence or absence of this signaling adaptor (Fig. 3.2).  
However, we demonstrated that the ∆secA2 mutant is more sensitive to a MyD88 
dependent antimicrobial response, a novel finding.  This suggests that virulent wild type 
M. tuberculosis is able to protect itself against this MyD88 dependent antimicrobial 
mechanism.  In contrast to ∆secA2 mutant, the attenuated strain H37Ra still demonstrates 
a growth defect in MyD88-/- macrophages.  This is a demonstration that the MyD88 
macrophages are still capable of inhibiting the growth of certain attenuated strains of 
mycobacteria, and that the growth of the ∆secA2 mutant in these cells is not due to a 
pleiotropic deficiency of all innate responses.  It also indicates that the basis of 
attenuation between H37Ra and ∆secA2 mutant is different.   
How does MyD88 contribute to controlling the growth of the ∆secA2 mutant?  
We have demonstrated that the attenuation of ∆secA2 mutant is not due to host 
mechanisms of ROI/RNI/cytotoxicity.  We demonstrated that the more robust host 
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responses induced by the ∆secA2 mutant are not transient, and continue until the late 
stages of the macrophage infection.  This demonstrates that the cells infected with the 
∆secA2 mutant are subjected to prolonged stimuli and to the potential downstream 
signaling effects of TNF-α.  As described, TNF-α induction by M. tuberculosis is 
MyD88 dependent.  We hypothesized that this host effector may be mediating an 
antimicrobial response against the ∆secA2 mutant.  We demonstrated that TNF-α is 
mediating antimicrobial effects against the ∆secA2 mutant, and that wild type M. 
tuberculosis is resistant to TNF-α mediated growth inhibition.   
What are the inhibitory effects mediated by TNF-α?  A previous report 
demonstrated that TNF-α can trigger growth inhibition of mycobacteria in an iNOS 
dependent manner (7).  However, this report also described a TNF-α dependent, iNOS 
independent mechanism of growth inhibition.  This was corroborated by another report, 
which demonstrated that the attenuated strain H37Ra was unable to replicate in 
macrophages from wild type, iNOS-/-, or IFN-γ-/- mice, but replicated to wild type levels 
in macrophages from TNF-α-/- mice (33).  Our data using the ∆secA2 mutant of M. 
tuberculosis mirrors these previously published reports, in that the ∆secA2 mutant is 
attenuated for growth in macrophages form wild type and iNOS-/- mice, but grows to wild 
type levels in macrophages from TNF-α-/- mice (this work, (46)).  Bekker etal suggest 
that the TNF-α dependent/iNOS independent inhibitory pathway could be via the 
induction of ROI through phox (7).  However, we have previously tested the growth of 
the ∆secA2 mutant in macrophages derived from two strains of mice deficient in different 
components of phox, and the ∆secA2 mutant was as attenuated in these cells as in those 
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derived from wild type mice (46).  This suggests, at least in the case of the ∆secA2 
mutant, that there must be another mechanism of inhibition at work.  One potential 
effector of the iNOS-independent mechanism is β-chemokines, whose expression are 
modulated by TNF-α and have been shown to play a role in inhibiting M. tuberculosis 
intracellular growth, in an as yet undetermined fashion (66).  At this point, we have not 
proven the TNF-α mediated effect on the mutant is due to the increased levels of TNF-α 
induced by the ∆secA2 mutant.  Alternatively, the ∆secA2 mutant may be defective in 
inhibiting a TNF-α dependent antimicrobial response. 
 The ability of M. tuberculosis to replicate in host cells is due to its ability to 
modulate the intracellular environment to favorable growth conditions, including 
modulating the cell death pathways triggered during infection.  It has been demonstrated 
that the intracellular replication of mycobacteria can be inhibited by the induction of 
apoptosis (32, 40, 52, 55).  Avirulent strains of M. tuberculosis have been shown to 
induce higher levels of apoptosis than virulent strains, by a mechanism linked by several 
groups to levels of bioactive TNF-α (1, 5, 22, 40, 41, 59, 63, 64, 73, 74).  However,  Park 
et al compared strains of M. tuberculosis for their ability to induce TNF-α and cell death 
by apoptosis or necrosis (56).  They demonstrate that strains inducing increased levels of 
TNF-α also induce higher levels of cell death, but that the cytotoxicity was resultant of 
necrotic death, versus apoptosis (56).  The differences in experimental design, types of 
cells used, and strains used are all variables that may contribute to the disparity in 
findings.  In our experimental system, we tested the wild type M. tuberculosis and 
∆secA2 mutant for their ability to induce cytotoxicity.  We found that the ∆secA2 mutant 
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in fact caused less cytotoxicity than the wild type, and even found less overall cell death 
than in uninfected cells.   
  It has been demonstrated that cells in vitro stimulated with exogenous TNF-α 
alone do not produce an antimicrobial response against M. bovis (19, 29).  We 
hypothesize that in our system, increased levels of TNF-α alone may not be causing an 
antimicrobial effect, that it is the synergy of TNF-α and an as yet undetermined factor, 
that invoke an antimycobacterial response. 
To explain our data, we proposed that M. tuberculosis limits MyD88 signaling, 
thereby inhibiting MyD88 dependent host antimicrobial responses.  We have 
demonstrated that MyD88 mediates an antimicrobial response against M. tuberculosis, as 
shown by the MyD88 dependent growth inhibition of the ∆secA2 mutant.  Therefore, 
altering the MyD88/TLR host signaling cascade may promote the survival of M. 
tuberculosis.  A recent report demonstrates the first evidence that to support the model 
that M. tuberculosis can suppress MyD88/TLR signaling through an inhibition event 
(58).  ESAT-6 is an antigen exported by M. tuberculosis by the specialized esx export 
pathway.  To inhibit the TLR response, ESAT-6 binds to TLR2, and suppresses 
downstream TLR signaling by inhibiting interaction of MyD88 and its catalytic partner 
IRAK4.  This abrogates the signaling of MyD88, and blocks the induction of cytokines 
such as IL-12 and TNF-α (58). This is consistent with published phenotypes of an ESAT-
6 mutant, or mutants in the esx export pathway, which induce more robust TNF-α and 
RNI responses during infection of murine macrophages and are attenuated for growth 
(50, 75).  This is likely due to the loss of the TLR inhibitory actions of ESAT-6.  ESAT-6 
mutants and ∆secA2 mutant of M. tuberculosis both induce a more robust cytokine 
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response and are attenuated.  However, we do not believe the phenotypes observed with 
the ∆secA2 mutant are due to a loss of ESAT-6, as we observe no decrease in ESAT-6 
export in the ∆secA2 mutant (data not shown).  It is interesting to speculate however, that 
there is a SecA2 dependent molecule that has a function similar to that of ESAT-6. 
An alternative to SecA2 having a direct inhibitory role for TLR/MyD88 signaling 
is the possibility that it has a role in assembling the cell envelope in a way to make it less 
stimulatory to the host cells.  This role may be to mask a TLR ligand, or to modify a 
ligand in a way that it is no longer recognized by TLR.  The ∆secA2 mutant may be 
missing a factor that alters the surface of the bacterium, resulting in ∆secA2 mutant 
inducing a more robust immune response.  There are examples of surface modifications 
in M. tuberculosis that have roles in modulating the immune response.  
Lipoarabinomannan (LAM) is a component of the mycobacterial cell wall exposed to the 
host environment.  In the slow growing, pathogenic mycobacterium species M. 
tuberculosis and M. leprae, LAM is modified with a mannose, yielding manLAM.  Fast-
growing, non-pathogenic mycobacteria have unmodified LAM, termed araLAM (42).  
Modified manLAM is less stimulatory than the unmodified araLAM, and each has a 
differential signaling effect on the TLR pathway, as reviewed by (60).  It will be 
important to compare the cell wall components of the ∆secA2 mutant to those of wild 
type.  If LAM or other surface molecules are altered, they may be altering the interaction 
with the immune response. 
Recent evidence suggests that the TLR/MyD88 pathway may be a mechanism by 
which phagosome maturation is triggered.  The model proposed for this action begins 
with the phagocytosis of a pathogen containing TLR ligands, and is reviewed by Blander 
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(8).  TLRs, and subsequently MyD88 are recruited to the vacuole and engage 
downstream signaling molecules.  Triggering of this signaling cascade results in a rapid 
maturation of the phagosome and fusion with lysosomes, which results in growth 
inhibition of E. coli (9).   In the absence of MyD88, there is a delay in 
phagosome/lysosome fusion and killing of E. coli (9).  However, other reports 
demonstrate that MyD88-/- macrophages have comparable, or even increased levels of 
antimicrobial activity to wild type macrophages, indicating pathogen specific effects (10, 
53, 82).  If the ∆secA2 mutant is altered in a way that it has an increased signaling 
through TLR/MyD88, then perhaps in addition to triggering an increased cytokine and 
RNI responses, the mutant is also engaging a heightened degree of phagosome/lysosme 
fusion through this signaling pathway, resulting in growth inhibition.  Yates et al (83) 
also demonstrate that MyD88 is important for phagosome/lysosome fusion; however, 
they suggest the function is independent of TLR engagement.  A role for MyD88 in 
phagosome/lysosome fusion may help explain the MyD88 dependent nature of the 
attenuation of ∆secA2 mutant.  It is an attractive possibility that the ∆secA2 mutant 
induces increased signaling through MyD88, which results in increased 
phagosome/lysosome fusion, inhibiting the growth of the mutant.   
While the exact mechanism is still undetermined, we have demonstrated that there 
is a MyD88 dependent antimicrobial response against M. tuberculosis, the first finding of 
its kind in a cell autonomous macrophage infection system.  We also know that the 
inhibitory effects of MyD88 on the growth of the ∆secA2 mutant are dependent on TNF-
α, but independent of ROI/RNI/cell death.  We propose a model, in which SecA2 of wild 
type M. tuberculosis promotes survival in the presence of a MyD88 dependent, TNF-α 
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dependent antimicrobial response.  SecA2 may export factors that limit signaling or 
actively inhibit the antimicrobial response.  When SecA2 is missing, the bacteria can no 
longer modulate the MyD88 response, resulting in increased levels of TNF-α, and an 
increased antimicrobial effect. However, without further investigation, more complex 
possibilities can not be ruled out.  Our findings have revealed a potentially novel 
mechanism by which host cells are able to inhibit the growth of M. tuberculosis, 
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The ∆secA2 mutant of Mycobacterium tuberculosis displays an altered colony 
morphology (Smooth) when compared to that of the wild type (Rough) on agar plates in 
the presence of Tween 80.  The Smooth ∆secA2 colonies are able to give off Rough 
variants at a relatively high frequency.  The Rough phenotype does not seem to switch 
back to Smooth.  We hypothesize that the change in colony morphology is due to an 
alteration in the cell envelope of the mutant.  The alteration is likely due to a defect in 
exporting a protein to the cell surface or due a defect in exporting a biosynthetic enzyme 
important for lipid modifications.  This alteration in the surface structure of the ∆secA2 
mutant could be linked to its growth defect in macrophages or altered immunomodulatory 
properties.  Understanding the colony phenotype may give us a better understanding of 
the role of SecA2 in virulence and physiology.  This may also help us to better 
understand the role of SecA2 in the basic biology of M. tuberculosis, specifically to 





 The architecture of bacterial envelopes is complex, and the composition of the 
cell envelope of M. tuberculosis is no exception to this.  As reviewed by P. Brennan (10), 
the mycobacterial cell envelope is comprised of the cell wall and cell membrane 
subcellular components.  The cell wall itself is a unique layered structure including 
peptidoglycan, arabinogalactan, mycolic acids, protein and other longer chain fatty acids.  
Several of the components found in the cell envelope are unique to mycobacteria.  As is 
found in other bacteria, there are many components of the cell envelope of mycobacteria 
that are important for virulence (2).  It is also not surprising that, mutations in proteins 
that are localized to the cell envelope often alter the surface phenotype of the bacterium, 
resulting in an altered colony morphology when the strains are grown on solid medium 
(4, 5, 13-15).   
There is a long history of alterations in the colony morphology of M. tuberculosis 
being associated with changes in virulence.  A 1947 report by Gardner Middlebrook etal 
(25) investigated the colony morphologies of virulent H37Rv and avirulent H37Ra and 
M. bovis BCG strains of mycobacterium using plates containing various concentrations of 
Tween 80.  As shown in the reproduction in Fig. 4.1A, they documented the appearance 
of colonies from all strains, virulent or attenuated, on plates that did not contain Tween as 
being rough, with a serpentine looking structure.  On plates with high concentrations of 
Tween, they also observed that colonies from both avirulent and 
 virulent strains had a similar morphotype, and looked smooth and domed.  However, 
plates with an intermediate concentration of Tween revealed a differential colony 
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morphology between virulent and avirulent strains.  On these intermediate Tween plates, 
the virulent H37Rv strain looked rough and serpentine, much as it had on plates without 
Tween.  In contrast, at the intermediate Tween concentrations the avirulent strains H37Ra 
and M. bovis BCG looked smooth and domed, similar to the morphology seen on plates 
with high Tween concentrations.  The overall observation was that the more avirulent the 
strain, the more smooth it looked on intermediate concentrations of Tween.  However, on 
plates with no Tween or high Tween concentrations, the avirulent strains were 
indistinguishable from the virulent one.   
The SecA2 alternate secretion pathway in M. tuberculosis plays a role in the export of 
a small set of proteins into the culture filtrate (9).  This pathway contributes to the 
virulence of M. tuberculosis, as a ∆secA2 mutant is attenuated in a whole animal model 
of infection, as well as in macrophages (9, 22).  The ∆secA2 mutant induces a more 
robust immune response compared to the wild type M. tuberculosis, and macrophages 
infected with the ∆secA2 mutant produce increased levels of reactive nitrogen 
intermediates (RNI) and proinflammatory cytokines such as TNF-α and IL-6  than those 
infected with the wild type (22). 
As we will demonstrate, the ∆secA2 mutant of M. tuberculosis has an altered colony 
morphology when cultured on plates supplemented with Tween 80, and colonies look 
smooth and domed (Smooth), compared to the wild type colonies which are rough and 
serpentine (Rough).   The phenotype of the ∆secA2 mutant is similar to the altered colony 
phenotype described by Middlebrook etal in 1947 for the attenuated strains M. bovis 
BCG and H37Ra (25).  This interesting finding suggested that SecA2 promotes the 
proper cell envelope architecture of M. tuberculosis.  Also, given the similarity between 
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the altered morphology of the ∆secA2 mutant to that of the avirulent strains H37Ra and 
M. bovis BCG, we hypothesized that the changes in the cell envelope of the ∆secA2 
mutant may be playing a role in its attenuation.  For these reasons, we performed 
experiments to begin characterization of the surface phenotypes of the ∆secA2 mutant. 
The Smooth phenotype of the mutant can revert back to Rough, and we have 
examined the selective pressures that Tween 80 play in the reversion.  The altered colony 
morphotype of the ∆secA2 mutant can be complemented by adding back an additional 
copy of secA2, demonstrating that the surface alteration is directly linked to SecA2.  In an 
attempt to elucidate the biochemical basis for the surface alteration, we have also isolated 
cosmid clones containing non-secA2 genes that can suppress the Smooth phenotype of 
the mutant. 
The relationship between M. tuberculosis and the host response is a complex one, and 
many surface and secreted lipids, proteins and lipoproteins interact with the host immune 
system (20).  It is interesting to speculate that the surface changes of the ∆secA2 mutant 
may be contributing to the attenuation and altered stimulation of the host immune 
response described in previous chapters.  SecA2 may contribute to pathogenesis by 




Materials and Methods 
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Bacterial Strains and Growth Conditions 
The Mycobacterium tuberculosis strains used in this study H37Rv, mc23112 Sm#2 and 
MBTB6 (individually isolated ∆secA2 mutants, stocks derived from a single colony for 
each), mc23111 (merodiploid strain used to generate the ∆secA2 mutants), mc23116 
(∆secA2, attB::secA2) (9), the attenuated strain H37Ra (ATCC 25177), and 
Mycobacterium bovis BCG strain Pasteur (from Dr. W.R. Jacobs, Jr.) (Statens Serum 
Institute vaccine strain) were grown in Middlebrook 7H9 broth (Difco) with 0.2% 
glycerol, 1X ADS (albumin dextrose saline), and 0.05% Tween 80 (Fisher).  When 
appropriate, the media was supplemented with the antibiotic kanamycin (20µg/ml) or 
hygromycin (50µg/ml).  For colony morphology experiments, the strains were plated 
onto Middlebrook 7H10 plates with 0.2% glycerol, 1X ADS (albumin dextrose saline), 
supplemented with various concentrations of Tween 80. 
 
Colony Photomicrographs 
Strains were plated onto 7H10 ADS Gly plates with various concentrations of Tween 80 
(Fisher), and incubated for 3-4 weeks at 370C.  An Olympus DP70 Digital Microscope 
camera system (a kind gift from Dr. Janne Cannon) was set-up in a biological safety 






The strains were cultured in 7H9 ADS Gly 0.05% Tween 80 to mid-logarithmic phase.  
The optical density of the cultures was determined, and the concentration of the strains 
was adjusted to 1 x 108 colony forming units (CFU)/ml in culture media with 0.05% 
Tween 80.  A 5µl sample of each strain was pipetted into a well of a tissue culture treated 
2-well chamber slide (Lab-Tek), spread onto the slide and allowed to air dry.  When dry, 
1ml of culture media containing 0.05% Tween 80 was gently pipetted onto the well.  The 
inoculated chamber slides were enclosed in a Tupperware container and incubated at 
37oC without shaking for 2-3 weeks in a 5% CO2 incubator .  After incubation, the media 
was pipetted off the slides, and the slides were allowed to dry before being fixed in 10% 
formalin.  After fixation, the slides were stained using the Difco TB Fluorescent Stain kit 
and visualized using a Nikon Eclipse E600 florescence microscope.   
 
Sodium dodecyl sulfate (SDS) Sensitivity Assay 
Bacteria were grown in 7H9 ADS Gly 0.05% Tween 80 to mid-logarithmic phase, 
washed and resuspended in PBS 0.05% Tween 80 to 1 x 107 CFU/ml.  SDS was added to 
a final concentration of 0.05%, and samples were incubated at 37oC with shaking.  Each 
strain was tested in triplicate, and samples were plated immediately after the addition of 
SDS and 24 hours later for enumeration of CFU.   
 
Scanning Electron Microscopy (SEM) 
Single colonies of H37Rv and the ∆secA2 mutant were resuspended in 300µl of PBS 
0.05% Tw80, then an equal volume of EM fixative (2% glutaraldehyde in 0.1M sodium 
cacodylate, pH 7.4) was added for one hour.  Fixed samples were processed by the 
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University of North Carolina Microscopy Services Laboratory and mounted for Scanning 
Electron Microscopy.  Samples were visualized over a range of magnifications on a 
Cambridge S200 SEM. 
 
Southern Blot 
Genomic DNA was prepared from H37Rv, ∆secA2 mutant, and each of the 28 Rough 
library clones as described (6).  A Southern blot was performed using the same 
conditions and secA2 probe described in Braunstein etal (9).  The DNA was digested 
with EcoRI/HindIII and probed with plasmid pMB146, which contains secA2. 
 
Plasmids and cosmid library 
The H37Rv cosmid library was a kind gift from Dr. William R. Jacobs Jr. and was 
generated as described in (1).  Plasmid pMB162, a single copy vector that integrates at 
the attB site, was generated by Braunstein etal (9) and contains a kanamycin resistance 
cassette. 
 
Retrieval and sequencing of cosmids from chromosomes of Rough suppressing 
clones 
Cosmids were isolated from the genomes of the Rough clones as described by Pascopella 
etal (26), with some modification.  Genomic DNA from Rough clones was isolated and 
digested with PacI to release the cosmid insert (6).  This digested DNA mixture was 
ligated to PacI digested pYUB412 based cosmid arms containing cos sites.  This ligation 
was then packaged into lambda phage heads using the Stratagene GigaPack kit and 
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recovered by transduction in Escherichia coli as hygromycin resistant cosmids.  Primers 
used to sequence the cosmid ends: pYUB412out (5’ TGCCACCTGACGTCTAAGAA 
3’) and Hygout (5’GCATGCAAGCTCAGGATGTC 3’) 
 
Cosmid subcloning 
Cosmid DNA was digested with MluI.   Individual cosmid fragments were purified from 
an agarose gel and ligated into MluI digested pMB198.  pMB198 is an integrating single 




Colony replating assay to determine the role of Tween 80 in selecting for Rough 
revertants 
This assay is described in detail in the figure legend for Figure 4.5.  All plates used in this 
experiment were 7H10 ADS Gly plates.  When listed, Tween 80 (Fisher) was added to 
the plates at a final concentration of 0.05% Tw80.  To resuspend colonies and patches, a 
sterile wooden applicator stick was used to remove the colony/patch from the plate.  
Bacteria were resuspended in 500µl PBS 0.05% Tw80 in a microcentrifuge tube by 






The ∆secA2 mutant of M. tuberculosis has an altered colony morphology on plates 
with Tween 80.  When culturing the ∆secA2 mutant on 7H10 plates containing 0.05% 
Tween 80, referred to as an intermediate Tween concentration in Fig. 4.1B, we observed 
the majority of colonies were smooth and domed (Smooth).  However, reproducibly a 
small number of colonies were rough and serpentine (Rough).  The Rough colonies 
resembled the morphology of the parental wild type H37Rv.  We wanted to confirm that 
the Smooth phenotype that we were observing was due to the mutation in secA2, and not 
a second site mutation.  The ∆secA2 mutant of M. tuberculosis used in all our studies has 
an in-frame, complete deletion of secA2.  The morphology phenotype was complemented 
by adding back an wild type copy of secA2 on plasmid pMB162 (9).  This demonstrated 
that the altered phenotype is due to the mutation in secA2 (Fig. 4.1B).  In addition, we 
also used the original single-crossover merodiploid strain, mc23111 to generate a new 
∆secA2 mutant.  Of seven clones generated by a double-crossover event, four clones 
displayed the Smooth colony phenotype and three displayed the Rough phenotype. All 
four Smooth clones were determined by Southern Blot to be ∆secA2 mutants, and the 
three Rough clones were determined to be wild type recombinants (data not shown). This 
new ∆secA2 mutant clone was named MBTB6. This again demonstrated that the altered 
colony phenotype was due to the mutation in ∆secA2. 
 Given the similarity of the colony phenotype of the ∆secA2 mutant to the 
phenotypes described by Middlebrook etal in 1947 (Fig. 4.1A), we sought to replicate 
that experiment to see if our strains behaved similarly.  Cultures of wild type H37Rv, 
∆secA2 mutant, the complemented mutant, and the attenuated strain H37Ra were grown 
to mid-logarithmic phase, diluted in PBS with 0.05% Tween 80, and plated onto  
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Middlebrook 7H10 plates with various Tween 80 concentrations.  All strains displayed a 
similar colony phenotype on plates with no Tween; they were brittle looking and rough, 
and showed serpentine like cords on the colony surface (Fig. 4.1B).  On plates with 
intermediate Tween 80 concentrations (0.01-0.05%), we again saw that the ∆secA2 
mutant colonies were Smooth, compared to the Rough colonies of the wild type and the 
complemented strain.  The attenuated strain H37Ra, also one of the strains tested by 
Middlebrook, looked much like the ∆secA2 mutant producing smooth and domed 
colonies.  Interestingly, we have not observed Rough revertants produced by H37Ra.  At 
plates with high concentrations of Tween 80 (0.1-0.5%), we see that all strains are  
smooth and domed, with even the wild type colonies resembling those of the ∆secA2 
mutant and H37Ra. 
 H37Ra is strain with multiple attenuations, many of them still unknown (11, 23, 
26, 27).  Given the similarities in colony morphotype, we sought to determine if the 
Smooth colony morphology in H37Ra could be linked to a mutation in secA2.  We 
transformed H37Ra with the secA2 complementing plasmid pMB162 (9), and cultured 
the transformants on 7H10 plates with 0.05% Tween 80.  The transformants were still 
Smooth, suggesting that the phenotype in H37Ra is not directly linked to SecA2 (data not 
shown).  We also sequenced the secA2 gene in H37Ra and found 100% sequence identity 
to the H37Rv secA2 coding region (data not shown), and have observed the expression of 
SecA2 protein by Western blot (data not shown).  We conclude that the altered colony 
phenotype of H37Ra is not directly linked to a secA2 mutation.   
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The ∆secA2 mutant is more sensitive to killing by detergent.  The glossy, Smooth 
appearance of the ∆secA2 mutant colonies in the presence of Tween 80 suggested that the 
alterations in the cell envelope are making it more permeable to the disruptive detergent 
effect of Tween 80.  We hypothesized that the cell envelope of the mutant may be more 
sensitive to the harmful effects of detergent.  We tested the sensitivity of the wild type, 
the ∆secA2 mutant, and the complemented strain to another detergent, sodium dodecyl 
sulfate (SDS).  The strains were grown in broth to mid-logarithmic phase, washed and 
resuspended in PBS 0.05% Tween, and SDS was added to a final concentration of 0.05%.  
The samples were incubated at 37o, and the viability of the strains was determined 
immediately after added SDS and at 24hrs by plating.  The wild type viability decreased 
by approximately ten fold after 24hrs (Fig 4.2).  The ∆secA2 mutant was more sensitive 
to killing by SDS, and showed a fifty fold reduction in CFU (p=0.01 vs wild type).  The 
increased sensitivity of the ∆secA2 mutant was complemented by adding back a wild type 
copy of secA2.  This data demonstrates that the cell envelope of the ∆secA2 mutant is 
less resistant to the effects of detergent. 
 
The ∆secA2 mutant is defective for cording.  Mycobacteria under standing culture 
conditions have the ability to form serpentine cords as the bacteria align themselves in 
long rope like structures.  The ability of strains to cord has long been associated as a 
property of virulent, but not avirulent, mycobacteria (12, 18).  The avirulent strain H37Ra 
was directly compared to H37Rv for the ability to cord, and H37Ra was found to be 
defective for this process (16).  Other M. tuberculosis mutants with alterations in cell 
envelope metabolic pathways also have defects in cording, including the pca and kasB  
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mutants (17); (5).  Cording has also been linked to the ability for mycobacteria to form 
biofilms (19).  Given the similarity in altered colony morphotypes of the ∆secA2 mutant 
and H37Ra, we sought to determine if the ∆secA2 mutant had an altered cording 
phenotype.  Wild type, ∆secA2 mutant, and the complemented strain were inoculated into 
chamber slides and allowed to grow without shaking at 37oC for 3 weeks.  When the 
slides were fixed and stained, we observed that the wild type had formed highly ordered 
aggregates and had an abundance of serpentine cords (Fig 4.3).  However, the ∆secA2 
mutant bacilli were found in predominantly loose aggregates of only a few bacteria (Fig 
4.3).  The cording defect was restored by adding back a wild type copy of secA2 (Fig 
4.3).  The altered colony morphology of the ∆secA2 mutant and the defect in cording is 
consistent with the ∆secA2 mutant having an altered cell envelope structure that prohibits 
it from proper cell to cell interactions. 
 
There are no changes in bacterial organization of the ∆secA2 mutant visible by 
Scanning Electron Microscopy (SEM).  The demonstrated alterations in the surface 
structure of the ∆secA2 mutant colonies led us to examine the bacteria at the level of a 
single cell, to see if there was an altered aggregation or obvious surface defect present on 
the ∆secA2 mutant.  Single colonies from both the ∆secA2 mutant and wild type H37Rv 
were harvested from plates containing Tw80, resuspended in PBS 0.05% Tw80 and EM 
fixative, prepared and examined by SEM.  As shown in Fig 4.4, bacteria were examined 
at 3650X and 16000X magnification.  There were no obvious differences in the 
organization of the bacteria for either strain, the bacilli were of similar length and showed 





The frequency of the Smooth to Rough reversion on plates.  As mentioned, the 
Smooth colony phenotype of the ∆secA2 mutant can revert back to the Rough 
morphotype, as seen on plates with intermediate Tween 80 concentrations.  We typically 
observe 0-10% Rough clones in a given population on plates.  Interestingly, the 
frequency of Rough reversion seems to be dependent on the density of colonies on the 
plates.  We observe that there is an inverse relationship between the number of Rough 
revertants and the density of colonies, such that on high density plates (500-1000 
CFU/plate), there is a lower percentage of Rough clones than on low density plates (20-
100 CFU/plate).  Plates with an intermediate density have an intermediate frequency of 
Rough reversion.  We employed several different methods to determine the rate at which 
the Smooth ∆secA2 mutant was reverting to Rough.  For an initial examination, we took 
two individual Smooth colonies from 7H10 plates containing 0.05% Tween 80, 
resuspended them in PBS 0.05% Tween and plated them onto 7H10 0.05% Tween plates.  
For the first single colony, there were 102 Rough out of 19,000 total colonies examined 
total, for a frequency of 0.054%.  The second colony yielded a frequency of 456 Rough 
out of 17000 total CFU examined, a frequency of 2.7%.  This high frequency is similar to 
what is observed for phase variation (29), much higher than what would be expected for 
the rate of spontaneous mutation (less than ~1 out of 106) (24).  However, phase variation 
refers to a reversible switch, and out of approximately 70,000 colonies we have not 
observed any Rough clones reverting back to Smooth (29).   
Given the high frequency of reversion, we hypothesized that growth of the 
∆secA2 mutant on plates with Tween 80 was selecting for Rough revertants.  A second 
possibility was that the Tween 80 was simply revealing a phenotypic reversion that is 
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selected for by Tween 80 independent mechanisms.  We sought to investigate the 
selective pressures of Tween 80 on the reversion of the Smooth phenotype to Rough.  To 
determine whether Tween 80 is a selective pressure to enhance phenotypic reversion, we 
preformed a series of passages on media without Tween 80, as described in Fig. 4.5.  
 Step 1: A single Smooth ∆secA2 mutant colony was isolated from a 7H10 ADS 
Gly plates with 0.05% Tw80, resuspended in PBS 0.05% Tween 80 and replated onto 
plates with 0.05% Tw80.  This process was repeated a second time to achieve a purified 
clone.  Step 2: After the purification, three individual Smooth colonies (A,B,C) were 
selected, resuspended and plated onto plates with and without Tw80.  The plates with 
Tw80 were to determine the starting frequency of the Smooth to Rough reversion.  As 
shown in Fig. 4.5, the starting frequency of the clones on high density plates ranged from 
0-4.2% Rough.  As previously mentioned, the frequency of Rough revertants seems to be 
dependent on the density of colonies on the plate.  In this experiment, we observed at 
least two-fold higher Rough revertants on low density plates than on high density plates.  
As an example, using the data from all three colonies replated in Step 2, the frequency of 
revertants for the high density plates (approximately 1000 CFU/plate), was at least two 
fold lower than for low density (20-100CFU/plate).  Step 3: From each of the original 
colonies replated (A, B, C), 75 colonies from the plates without Tw80 were taken and 
patched onto plates with and without Tw80.  The patches on the plates containing Tween 
would allow us to confirm the Smooth phenotype of the clone before proceeding, so that 
no Rough clones would be replated in large scale.  The Smooth and Rough phenotypes 




+Tw80 plates.  We then took a patch from a plate without Tw80, and the corresponding 
patch from the plate with Tw80, and resuspended the patch and plated on a large scale, 
onto plates with Tw80.  Patches from each of the original clones A, B, C were tested, 
giving a total of six patches replated.  The suspensions were plated at a high density of 
approximately 500-1000 CFU/plate for a total of approximately 20,000 CFU derived per 
patch replated.  Of all patches replated from plates without Tw, no Rough clones were 
found of the 60,000 CFU examined.  A second experiment using another independently 
derived Smooth colony also yielded no Rough clones out of an additional 20,000 CFU 
screened.  The patches replated from plates with Tw80 yielded Rough clones at a 
frequency slightly lower than the starting frequency, ranging from 0.06-0.09% Rough.  
This data suggests that Tween is a selective pressure on plates for the reversion of a 
Smooth colony to Rough.  The results of this experiment suggest that propogating the 
strain on plates in the absence of Tween 80 will avoid selecting for Rough revertants.  
This will help to obtain a more pure colony population for future experiments. 
 
Testing the selective pressure of Tween 80 in liquid culture.  Given the high rate of 
Rough reversion on plates, we investigated the frequency of Smooth and Rough 
morphologies from broth grown cultures, which by necessity contain 0.05% Tween 80, to 
see if the Rough morphotype would accumulate in broth over multiple serial passages.  
The ∆secA2 mutant was cultured in triplicate in 7H9 broth containing 0.05% Tween 80, 
and each week 0.5ml of culture was diluted into 10ml of fresh media.  The ∆secA2 
mutant was passaged thirty times over the course of thirty weeks.  The cultures were 
plated on the first passage, and then plated during the course of the experiment to 
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evaluate the frequency of rough variants. The frequency of Rough revertants did not 
show a statistical increase over time (Table 4.1).  This suggests that although selection for 
the revertants occurs on plates containing Tween 80, and does not occur in liquid culture 
in the presence of Tween.  These experiments suggest that the procedure to achieve a 
homogeneous Smooth population would be to take a colony from a plate without Tween 
80, to patch that colony onto plates without Tween 80, then to take that patch and 
inoculate into liquid media.  Several rounds of patching on plates without Tween 80 may 
also be beneficial. 
Also, the reversion to a Rough phenotype does not seem to be selected for 
intracellularly in either murine bone marrow derived macrophages or the human 
monocytic cell line THP-1, as the percentage of Rough variants during the course of an 
infection does not vary (data not shown).  This may suggest that there is no survival 
advantage for one variant versus another in the macrophages.  Although, given the short 
time course of the experiments of six days (or 3-4 doublings), perhaps there is not enough 
time to select for an enriched population. 
 
 
Complementing the Smooth colony phenotype using an M. tuberculosis cosmid 
library.  The altered colony phenotype of the ∆secA2 mutant is likely due to diminished 
export of a cell envelope factor.   We hypothesized that if we were able to add an 
additional copy of the unknown factor, that increased levels of that protein might be able 
to suppress the ∆secA2 mutant phenotype.  We transformed a M. tuberculosis H37Rv 
genomic cosmid library (1) into the ∆secA2 mutant, in hopes of identifying genes that, 
when over-expressed in the ∆secA2 mutant background, would suppress the Smooth  
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phenotype back to Rough.  These factors would then lead us to the types of proteins that 
contribute to the Rough morphotype.  The cosmid library used has an average insert size 
of 30-40kb and integrates in single copy into the M. tuberculosis genome (1).  
Transformants were plated onto 7H10 plates supplemented with 0.05% Tween and 
hygromycin to select for the cosmids, and the colony phenotypes examined.  Out of 4648 
colonies, we isolated 28 Rough clones.  A control transformation using the cosmid 
backbone vector pYUB412 showed no Rough revertants out of 4500 clones.  The genome 
of M. tuberculosis is approximately 4Mb, so given the average cosmid insert size of 
35kb, we examined 40X genome equivalents represented by our 4648 cosmid clones.  
We generated genomic DNA from these 28 clones and performed Southern Blot analysis 
to determine if any of the Rough complementing cosmids contained secA2, using a 
strategy designed by Braunstein etal (9).  The secA2 probe hybridizes to an 11.4kb 
secA2-containing fragment in wild type, and a 3.5kb fragment in the ∆secA2 mutant (Fig. 
4.6).  Any Rough complementing clone that contains a cosmid with secA2 would have 
two bands: the ∆secA2 3.5kb fragment and an 11.4kb wild type fragment generated from 
the cosmid.  Two Rough complemented clones, Cosmid 23 and Cosmid 25, were found 
to contain an additional wild type copy of secA2 (Fig. 4.6).  
We next rescued the cosmids from the genomes by digesting genome DNA from 
the Rough cones, ligating the mixture to cosmid arms, and packaging the ligation into 
lambda phage.  The phage were used to transduce E. coli, and the cosmid clones were 
selected on hygromycin.  The ends of the retrieved cosmids were sequenced to determine 
the boundaries of the inserts.  To date, we have extracted the cosmids from 13 clones, and 
have sequenced the ends of inserts from 12 clones using primers which hybridize to the  
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vector (Table 4.2).  The sequence obtained from the cosmids suggests that there are 
several groups of cosmids that may share overlap in insert sequence.  However, given the 
nature of the cosmid library construction, there is a possibility that a single cosmid may 
contain more that one insert, or that the insert is scrambled.  Our sequence analysis 
determined that this was the case, and that at least five of our cosmid clones contained 
scrambled inserts (Table 4.2).  Cosmids 7 and 9 shared identical sequence overlap, 
demonstrating that these represented a single clone that was duplicated in the library or 
during outgrowth after library transformation.  Several cosmids were transformed back 
into the ∆secA2 mutant to confirm that the cosmid could complement the colony 
phenotype back to Rough, proving that the original cosmid clones were not 
spontaneously Rough.  Cosmids 6, 13, 11 and 21 were able to complement the ∆secA2 
mutant phenotype to the parental Rough.   
Sequence analysis and restriction digest mapping of Cosmid 21 demonstrated that 
the insert was 38kb, and may share sequence overlap with Cosmid 20.  The chromosomal 
region contained in the insert of Cosmid 21 is depicted in Fig. 4.7A.  To ascertain the 
gene responsible for complementation, Cosmid 21 was subcloned into smaller fragments, 
and the smaller subclones were tested for their ability to suppress the ∆secA2 mutant 
Smooth phenotype to Rough.  On Cosmid 21, the locus that was able to confer the Rough 
phenotype to the ∆secA2 mutant was identified as Rv3271c, and the suppressing 
fragment is represented in Fig. 4.7B.  Rv3271c was contained on a 1.5kb MluI fragment 
cloned into the integrating vector pMB198, which does not contain a constitutive 
fragment reveals several potential promoter regions.  The suppressing fragment also  
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Table 4.2 : Cosmids conferring the Rough colony morphotype to the 






















1 3411663 (F) Rv3050c     
3 3545572 
(R) 
Rv3177     
4 395073(R) Rv0329c   Cos6  
6 407119 (R) Rv0339c   Cos4  
7 281904 (R) Rv0235c 1603104 
(F) 
Rv1427c Cos9/ Hygout 
sequence may 
overlap with Cos13 
Cos7 and Cos9 are 
the exact same 
cosmid clone, and 
the cosmid is 
scrambled 
9 281904 (R) Rv0235c 1603104 
(F) 
Rv1427c Cos7/ Hygout 
sequence may 
overlap with Cos13 
Cos7 and Cos9 are 
the exact same 
cosmid clone, and 






Rv3756c Hygout may overlap 
with Cos14 
cosmid is scrambled 
13 726609 (R) Rv0631c 255333 Rv0213c Hygout may overlap 
with Cos7/Cos9 
 
14 3658440 (F) Rv3276c 4201382 
(R) 





Rv1166  cosmid is scrambled 
17 893542 (R) Rv0800 222342 (R) Rv0190 Hygout sequence 
may overlap with 
Cos18 
cosmid is scrambled 
18 222342 (F) Rv0191     
19 1772933 (F) Rv1565c     
20   3673602(R
) 
Rv3292 Insert may overlap 
with Cos21/Cos28 
 
21 3636275(F) Rv3257c   Insert may overlap 
with Cos20/Cos28 
Cosmid subcloned 
23      Contains secA2 
24 355888 (F) Rv0292     
25      Contains secA2 
28 3642809 (F) Rv3262 3682376 
(R) 





1These represent the Rough complementing clones for which sequence information is known 
2 The rescued cosmids were sequenced using primers derived from the pYUB412 cosmid backbone, Forward (412out1) 
and Reverse (Hygout).  The number represents the location on the H37Rv genome (Tuberculist) where the sequence 
alignment begins 
3 The directionality of the sequence as read from the pYUB412 backbone, to determine the orientation of the insert 
4 The open reading frame on the H37Rv genome where sequence alignment begins 
5 If the cosmid sequence suggests potential overlap with another cosmid clone, that clone is listed in this column. Given 
the potential for scrambled inserts, there may be only partial overlap 
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contained two other truncated proteins, including the first 19aa of CtpC and the first 
253aa (of 349aa total) of Rv3272, however Rv3271c was the only complete reading 
frame contained within the fragment cloned.  This open reading frame (orf) corresponds 
to a protein annotated in the M. tuberculosis H37Rv genome as a probable conserved 
integral membrane protein.  In silico analysis of Rv3271c reveals six transmembrane 
helices, but no cleavable signal peptide.  There have been no functional studies to date on 
this protein, however, homology searches show similarity to cation efflux proteins.  A 
saturating transposon mutagenesis of M. tuberculosis identified this gene as one that is 
likely to be essential for the optimal growth of M. tuberculosis (28).   
 Taken together, our data supports that there is an altered cell surface of the 
∆secA2 mutant of M. tuberculosis by multiple evaluations.   We have demonstrated that 
the ∆secA2 mutant of M. tuberculosis displays an altered colony phenotype, perhaps due 
to an increased sensitivity of the ∆secA2 mutant cell envelope to the detergent properties 
of Tween 80.  The ∆secA2 mutant has altered cell to cell interaction, as shown by the 
defect in cording.  We have uncovered an integral membrane protein, Rv3271c, which 
can suppress the altered morphotype.  Further examination of the other complementing 
cosmids may lead to a better understanding of the changes in the cell envelope of ∆secA2 
mutant, as well as a direct examination of the cell envelope and its properties.  Achieving 
a better understanding of the behavior and biology of the ∆secA2 mutant may give us a 
better understanding of SecA2 dependent factors important for the normal processes and 






 The ∆secA2 mutant of M. tuberculosis has an altered colony phenotype on plates 
supplemented with Tween 80, a phenotype similar to that described for the attenuated 
strains H37Ra and M. bovis BCG in 1947 (25).  Interestingly, the Smooth phenotype 
observed in the ∆secA2 mutant is unstable, and clones revert back to the wild type Rough 
morphotype at a relatively high frequency when plated on agar with Tween 80.  Our 
experiments demonstrating the selective pressure of Tween 80 on the reversion, as well 
as the increased sensitivity of the ∆secA2 mutant to SDS, suggests that there are 
alterations in the cell envelope of the ∆secA2 mutant that make it more sensitive to the 
disruptive properties of detergent.  Perhaps the instability of the cell envelope is driving 
the selection of a more stable, Rough revertant.  As mentioned previously, we observe a 
higher frequency of Rough revertants on plates with a lower density of colonies.  This 
may suggest that Tween 80 is having a toxic effect on the Smooth bacteria, and that at 
higher densities the toxic effects of Tween 80 are titrated away by the bacteria, perhaps 
by a secreted factor that is able to breakdown the Tween.  More studies will have to be 
done to determine what the effects of Tween 80 are. 
As there were no visible differences in the morphology of the individual bacilli, it 
raises the questions as to what the altered cell envelope properties of the ∆secA2 mutant 
are.  We hypothesize that SecA2 exports a cell envelope associated factor, or a 
biosynthetic enzyme that modifies the cell envelope.  We attempted to isolate sequences 
of the genome that could suppress the Smooth morphotype of the ∆secA2 mutant.  We 
hypothesized that if we were able to add an additional copy of the unknown factor, 
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increased levels of that factor would be able to suppress the ∆secA2 mutant phenotype.  
We isolated several unique clones that are able to restore the wild type Rough 
morphotype.  Subcloning from one of the Rough cosmids yielded a single locus that we 
were able to identify, Rv3271c, is annotated as an essential, putative integral membrane 
protein.  In silico analysis suggests that Rv3271c is an integral membrane protein, 
supporting idea that alterations to the membrane can cause the phenotypic reversion.  
When an additional copy of this gene is expressed under the control of its own promoter, 
it may alter the surface or protein interactions of the cell envelope.  Given the nature of 
this system, we may simply be screening for genes that, when presented in an extra copy 
change the surface composition.  Further studies will be needed to determine if the genes 
we isolated that suppress the Smooth phenotype are SecA2 specific.  We hypothesize that 
there may be several categories of factors that can suppress the Smooth phenotype.  
There may be membrane and secreted proteins that are directly involved with cell 
envelope structure.  Alternatively, there may be biosynthetic enzymes that modify cell 
envelope associated lipids.  There may be multiple factors that contribute to the 
Smooth/Rough phenotype.  Isolation of the other loci responsible for suppression may 
give more insight to the nature of the cell envelope perturbation in the ∆secA2 mutant. 
The ∆secA2 mutant of M. tuberculosis is attenuated in a murine model of 
infection (9, 22).  In murine macrophages, the ∆secA2 mutant is attenuated for growth, 
and hyperactivates the macrophages to produce increased levels of proinflammatory 
cytokines TNF-α and IL-6 and reactive nitrogen intermediates (RNI) (22).  The alteration 
of the cell envelope in the ∆secA2 mutant may contribute to its attenuation by changing 
the interation of ∆secA2 mutant with the immune system. Given the instability of the 
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colony morphotype of the ∆secA2 mutant, it is important to establish the virulence of the 
Rough revertants in the mutant background.  The factors in the ∆secA2 mutant that are 
inducing the more robust immune response discussed in Chapter 3 and Chapter 4 may be 
related to its altered cell wall.  If so, then the Rough revertants may have reestablished 
some of the wild type characteristics, and may no longer induce a more robust response.  
As we have discussed in Chapter 4, this more robust response may be directly related to 
the attenuation of the ∆secA2 mutant.  Therefore, if a given population of ∆secA2 mutant 
culture has more Rough revertants, it may be more virulent than a pure Smooth 
population, and may be confounding our studies.  However, as mentioned previously 
there does not seem to be an accumulation of the Rough revertants over time in 
macrophages cultures.  Nonetheless, our results have demonstrated a way that the ∆secA2 
mutant can be propogated in order to give the most pure Smooth population.  If the strain 
is cultured on plates without Tween 80, and subsequently inoculated into liquid media 
from the plates without Tween, this should minimize the level of Rough revertants. It is 
still important to determine the virulence properties of these Rough revertants. 
The proper localization of cell envelope components is important for virulence in 
many organisms, including M. tuberculosis, and the alterations in the cell envelope of the 
∆secA2 mutant may be contributing to its attenuation.  There are several mutants of M. 
tuberculosis that demonstrate an altered colony morphology and that are attenuated for 
virulence.  KasB is an enzyme required for the biosynthesis of mycolic acids, an integral 
component of the cell envelope of M. tuberculosis.  A kasB mutant is defective for 
cording as mentioned previously, and has an altered colony morphotype (5).  This mutant 
is highly attenuated in mice (5).  Phthiocerol dimycocerosates (PDIM) is a cell envelope-
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associated lipid found only in pathogenic mycobacteria.  A screen of a transposon mutant 
library for attenuated mutants of M. tuberculosis revealed three mutants to be avirulent, 
in pps, FadD28 and mmpL7, that were each involved in the biosynthesis and localization 
of PDIM (13).  These mutants also had altered colony morphotypes when compared to 
the wild type strain.  Proteins localized to the surface of the bacterium can also contribute 
to the overall cell envelope architecture of the bacterium.  The exported repetitive protein 
(Erp) is surface exposed in M. tuberculosis and M. bovis BCG (4, 14, 15).  When erp is 
disrupted, the resulting strain of M. tuberculosis is attenuated (4, 14).  The ∆erp strain 
also has an altered colony morphology compared to the parental wild type (4, 14, 15).  
However, the altered colony morphotypes of these mutants done by visual comparison of 
published colony micrographs, do not resemble those of the ∆secA2 mutant, suggesting 
that the alterations in the ∆secA2 mutant may be unrelated to these described cell 
envelope components. It may be worthwhile to examine these described mutants in 
parallel to the ∆secA2 mutant to confirm that they do not share similar characteristics.   
The colony and cording phenotypes of the ∆secA2 mutant most closely resemble 
those of the attenuated strain H37Ra (25).  Our studies indicate that the altered phenotype 
of H37Ra is independent of secA2.  One group examined gene expression profiles of 
H37Rv and H37Ra grown under several conditions in which the wild type showed the 
cording phenotype and H37Ra did not (16).  Under these conditions, there were 22 genes 
consistently downregulated in H37Ra, a significant population of which represented 
genes involved in lipid metabolism and cell membrane processes.   
Also in Mycobacterium kansasii, there are similar Rough and Smooth colony 
morphotypes when grown on plates containing Tween 80 (3).  Analysis of cell envelope 
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components showed that the lipooligosaccharide of the Smooth strain contained 
trehalose, while that of the Rough strain did not.  The Smooth morphotype of M. kansasii 
was less virulent than the Rough strain, which was able to persist longer in mice.  Given 
the similarities in the phenotypes of these strains, these may be attractive candidates to 
investigate in the ∆secA2 mutant.   
We have presented data that the ∆secA2 mutant of M. tuberculosis induces a more 
robust immune response.  Because SecA2 is a secretion factor, its role in 
immunomodulation is most likely related to proper secretion or cell wall localization of 
an immunosuppressive factor.  Alternatively, SecA2 may secrete an enzyme that 
modifies a cell wall factor to make it less immunogenic.  However, all of the proteins 
localized by SecA2, particularly cell wall proteins, are not yet known.  The mycobacterial 
cell wall is a complex structure that contains many diverse molecules with reported 
immunomodulatory properties (21).   The increased immune response elicited by the 
∆secA2 mutant could be explained by different amounts of immunoregulatory molecules 
in the cell wall or an altered cell wall structure with greater exposure of stimulatory 
molecules that interact with host receptors.  Thus, we are considering the possibility that 
the immunosuppressive effect of SecA2 is due to a role in localization of cell wall 
synthetic enzymes that influence cell wall architecture.  A final possibility is that the 
∆secA2 mutant phenotypes actually represent increased release of a stimulatory molecule 
(8).  
Overall, we are just beginning to understand the role that SecA2 plays in the 
establishment of the cell envelope architecture and how that may affect the virulence of 
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the organism.  Achieving a better understanding of the SecA2 dependent factors that alter 
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 An estimated 1.6 million people died from tuberculosis in 2005, an equivalent of 
4400 people per day (3).  The continuing tuberculosis pandemic burdens the global health 
care system, and a better vaccine and improved anti-mycobacterial therapies are needed 
to control this health crisis.  It is essential that we achieve a greater understanding of the 
biology of M. tuberculosis and how it combats the host immune response to help 
eradicate this disease.  
 For many pathogens, the full virulence of the organism is dependent on accessory 
secretion systems and secreted virulence factors.  For mycobacteria and some Gram 
positive pathogens, the roles that these alternate secretion systems play in pathogenesis 
are only beginning to be uncovered.  In Chapter 2, we present data that demonstrated the 
accessory SecA2 secretion system of M. tuberculosis to be essential to the full virulence 
of the organism.  We further showed that a ∆secA2 mutant of M. tuberculosis is 
attenuated for growth in non-activated murine bone marrow derived macrophages.  The 
ability of M. tuberculosis to replicate in macrophages relies on a complex array of 
virulence traits.  These include M. tuberculosis overcoming the toxic effects of reactive 
oxygen (ROI) and reactive nitrogen intermediates (RNI) in order to survive, as reviewed 
in (2).  However, the ∆secA2 mutant phenotype is not due to an inability to resist these 
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host defense mechanisms.  The ∆secA2 mutant is equally attenuated in macrophages from 
phox-/- or iNOS-/- mice, which are deficient for ROI and RNI respectively, as it is in cells 
from wild type mice.  We also demonstrated that macrophages infected with the ∆secA2 
mutant produce a more robust immune response than those infected with the parental 
wild type M. tuberculosis.  This led to our hypothesis that SecA2 promotes virulence of 
M. tuberculosis by modulating the host immune response. 
In Chapter 3, we investigated alternate host factors that might be contributing to 
the attenuation of the mutant.  Macrophages infected with the ∆secA2 mutant produced 
increased levels of the proinflammatory cytokines IL-6 and TNF-α, as well as increased 
RNI.  M. tuberculosis induces the production of these proinflammatory molecules 
through TLR/MyD88 dependent signaling cascade, as reviewed by (1).  The role of 
SecA2 may be to inhibit the TLR/MyD88 dependent immune response.  We 
hypothesized that if the mutant is stimulating a more intense TLR response, perhaps the 
host factors induced by this pathway control the growth of the mutant.  We tested this 
hypothesis by examining the growth of the ∆secA2 mutant in macrophages derived from 
mice deficient in MyD88. We observed that the attenuation of the ∆secA2 mutant is 
reversed in the MyD88-/- macrophages.  This data proposes a role for the TLR/MyD88 
signaling pathway in the growth inhibition of the ∆secA2 mutant.  More specifically, this 
data suggests that there is a MyD88 dependent mechanism that inhibits the growth of M. 
tuberculosis.  However, virulent M. tuberculosis is able to overcome this host defense 
mechanism to grow intracellularly.  MyD88 is a downstream signaling adaptor for the 
individual TLRs, therefore it will be interesting to investigate the contribution of the 
individual TLR molecules to the attenuation of the mutant. 
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 Given the increase of TNF-α during infection with the ∆secA2 mutant, we tested 
the role of this cytokine in the attenuation of the mutant.  Our data demonstrates that a 
TNF-α dependent host response is required for the attenuation of the ∆secA2 mutant.  In 
our cell autonomous macrophage infection, TNF-α directs an antimicrobial mechanisms 
against ∆secA2 mutant.  However, wild type M. tuberculosis is able to overcome this 
TNF-α dependent response.  
There are several potential mechanisms used by the host to control the growth of 
M. tuberculosis.  We have demonstrated that the ∆secA2 mutant is attenuated by a host 
response mechanism that is dependent on MyD88 and TNF-α, yet independent of ROI, 
RNI, or host cell cytotoxicity.  Further investigations will be needed to uncover this novle 
MyD88/TNF-α dependent antimicrobial mechanism.  
 We propose two models for the role of SecA2 in promoting the growth of M. 
tuberculosis in host macrophages.  In the first model (Fig. 5.1), M. tuberculosis produces 
immunomodulatory proteins that are exported via SecA2.  The ∆secA2 mutant is 
deficient for the export of these immunomodulatory proteins, and therefore can not 
properly alter the host cell environment into one favorable for replication  
The second proposed model of the role of SecA2 in modulating the host immune 
response is one where the surface exposed components of the cell envelope of M. 
tuberculosis contain modifications that decrease its ability to induce a TLR response, or 
mask exposure of a TLR ligand (Fig. 5.1).  In this model, the surface modifications 
would be dependent on factors localized by the SecA2 export pathway.  In the ∆secA2 
mutant these factors are absent, and the altered surface of the ∆secA2 mutant is more 
stimulatory.   
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In M. tuberculosis there are examples of exported factors that would support either 
SecA2 model of immunomodulation.  Further investigation is needed to determine which 
model is correct. 
In Chapter 4, we demonstrated that the ∆secA2 mutant of M. tuberculosis has an 
altered colony morphology (Smooth) on plates containing Tween 80 and is defective for 
cording.  This data suggests that there is some alteration in the cell envelope of the 
∆secA2 mutant.  We also saw that the ∆secA2 mutant is able to revert back to a wild type 
colony morphotype (Rough).  This reversion is dependent on the presence of the Tween 
80 in the plates.  The altered surface structure of the ∆secA2 mutant may correlate with 
our second model of how SecA2 functions to modulate the host immune response, by 
altering the surface of the bacterium to make is less stimulatory. We have proposed a 
method for culturing the ∆secA2 mutant in order to minimize the potential for Rough 
reversion.  It will be important to analyze the cell envelope fractions of the ∆secA2 
mutant to determine the factors contributing to the altered morphotype, as these may be 
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